nctid,version_number,total_versions,version_date,overall_status,study_start_date,primary_completion_date,primary_completion_date_type,enrolment,enrolment_type,min_age,max_age,sex,gender_based,accepts_healthy_volunteers,criteria,outcome_measures,contacts,sponsor_collaborators
NCT01669382,1,2,2012-08-20,Recruiting,2012-01-01,2012-09-01,Anticipated,304,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nall patients who receive coronary angiography/intervention with an 6 F sheath\n\nExclusion Criteria:\n\nsevere calcification of the access vessel,\nsevere peripheral artery disease,\npuncture in the origin of the profound femoral artery,\nnon-femoral sheath insertion,\nmarked turtuosity of the femoral or iliac artery,\nmarked obesity or kachexia (BMI >40 or <20)\npatients on continuous medication with oral anticoagulants.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bleeding, need for vascular surgery and device failure\n[ Time Frame: 24 hours ]\n\nbleeding, need for vascular surgery and device failure will be measured as primary endpoints within the first 24 hours.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""occurance of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device.\n[ Time Frame: 24 hours ]\n\nSecondary endpoints are the occurance of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device.""},{""section"":""Other Outcome Measures:"",""label"":""1."",""content"":""lab values\n[ Time Frame: 24 hours ]\n\nred blood count after 24 hours""}]","[{""label"":""Study Officials:"",""content"":""Harald Rittger, MD\nPrincipal Investigator\nUniversitätsklinikum Erlangen, Medizinische Klinik 2, Germany""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Erlangen""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Harald Rittger\n\nOfficial Title: Priv.-Doz. Dr. Harald Rittger\nAffiliation: University Hospital Erlangen""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01669382,2,2,2015-02-02,Completed,2012-01-01,2012-09-01,Actual,304,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nall patients who receive coronary angiography/intervention with an 6 F sheath\n\nExclusion Criteria:\n\nsevere calcification of the access vessel,\nsevere peripheral artery disease,\npuncture in the origin of the profound femoral artery,\nnon-femoral sheath insertion,\nmarked tortuosity of the femoral or iliac artery,\nmarked obesity or cachexia (BMI >40 or <20)\npatients on continuous medication with oral anticoagulants.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""bleeding, need for vascular surgery and device failure\n[ Time Frame: 24 hours ]\n\nbleeding, need for vascular surgery and device failure will be measured as primary endpoints within the first 24 hours.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""occurrence of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device.\n[ Time Frame: 24 hours ]\n\nSecondary endpoints are the occurrence of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device.""},{""section"":""Other Outcome Measures:"",""label"":""1."",""content"":""lab values\n[ Time Frame: 24 hours ]\n\nred blood count after 24 hours""}]","[{""label"":""Study Officials:"",""content"":""Harald Rittger, MD\nPrincipal Investigator\nUniversitätsklinikum Erlangen, Medizinische Klinik 2, Germany""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Erlangen""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Harald Rittger\n\nOfficial Title: Priv.-Doz. Dr. Harald Rittger\nAffiliation: University Hospital Erlangen""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00664963,1,3,2008-04-18,Recruiting,2006-04-01,2009-03-01,Anticipated,130,Anticipated,21,NA,All,NA,No,"[""Inclusion Criteria:\n\nClinical diagnosis of peripheral arterial occlusive disease as defined by Rutherford 2-5\nDe-novo stenosis of > 70% diameter stenosis in the tibioperoneal trunc, anterior and/or posterior tibial and/or peroneal artery\nTarget lesion length of ≤ 45 mm\n\nExclusion Criteria:\n\nCoagulation disorder\nKnown allergy to contrast medium\nContraindications to antiplatelet therapy or heparin""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Restenosis rate after 12 months (> 50% stenosis by angiography or duplex ultrasound)\n[ Time Frame: 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Number of reinterventions of target vessel\n[ Time Frame: 12 months ]""}]","[{""label"":""Central Contact Person:"",""content"":""Thomas Zeller, MD\nTelephone: +49 (0)7633 402 2431\nEmail: thomas.zeller@herzzentrum.de""},{""label"":""Central Contact Backup:"",""content"":""Aljoscha Rastan, MD\nTelephone: +49 (0)7633 402 2431\nEmail: aljoscha.rastan@herzzentrum.de""},{""label"":""Study Officials:"",""content"":""Thomas Zeller, MD\nPrincipal Investigator\nHerz-Zentrum Bad Krozingen""}]","[{""label"":""Sponsor:"",""content"":""Herz-Zentrums Bad Krozingen""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00664963,2,3,2009-02-09,"Active, not recruiting",2006-04-01,2010-03-01,Anticipated,130,Anticipated,21,NA,All,NA,No,"[""Inclusion Criteria:\n\nClinical diagnosis of peripheral arterial occlusive disease as defined by Rutherford 2-5\nDe-novo stenosis of > 70% diameter stenosis in the tibioperoneal trunc, anterior and/or posterior tibial and/or peroneal artery\nTarget lesion length of ≤ 45 mm\n\nExclusion Criteria:\n\nCoagulation disorder\nKnown allergy to contrast medium\nContraindications to antiplatelet therapy or heparin""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Restenosis rate after 12 months (> 50% stenosis by angiography or duplex ultrasound)\n[ Time Frame: 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Number of reinterventions of target vessel\n[ Time Frame: 12 months ]""}]","[{""label"":""Study Officials:"",""content"":""Thomas Zeller, MD\nPrincipal Investigator\nHerz-Zentrum Bad Krozingen""}]","[{""label"":""Sponsor:"",""content"":""Herz-Zentrums Bad Krozingen""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00664963,3,3,2014-12-16,Completed,2006-04-01,2010-03-01,Actual,130,Actual,21,NA,All,NA,No,"[""Inclusion Criteria:\n\nClinical diagnosis of peripheral arterial occlusive disease as defined by Rutherford 2-5\nDe-novo stenosis of > 70% diameter stenosis in the tibioperoneal trunc, anterior and/or posterior tibial and/or peroneal artery\nTarget lesion length of ≤ 45 mm\n\nExclusion Criteria:\n\nCoagulation disorder\nKnown allergy to contrast medium\nContraindications to antiplatelet therapy or heparin""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Restenosis rate after 12 months (> 50% stenosis by angiography or duplex ultrasound)\n[ Time Frame: 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Number of reinterventions of target vessel\n[ Time Frame: 12 months ]""}]","[{""label"":""Study Officials:"",""content"":""Thomas Zeller, MD\nPrincipal Investigator\nHerz-Zentrum Bad Krozingen""}]","[{""label"":""Sponsor:"",""content"":""Herz-Zentrums Bad Krozingen""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Prof. Dr. med. Thomas Zeller\n\nOfficial Title: Prof.\nAffiliation: Herz-Zentrums Bad Krozingen""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01601769,1,1,2012-05-16,Unknown status,2011-04-01,2012-07-01,Anticipated,300,Anticipated,NA,NA,Female,NA,No,"[""Inclusion Criteria:\n\nKarnowsky-Index > 80,\n18-80 years,\nCIN.\n\nExclusion Criteria:\n\nPregnancy,\nPrevious or current cancer,\nRadio therapy of the pelvis,\nSerious internistic accompanying diseases,\nPsychiatric diseases,\nHIV infection,\nDrug addiction.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cervical volume removed\n[ Time Frame: İmmediately after surgery ]\n\nCervical volume removed during the operation is recorded""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""İntraoperative Complications\n[ Time Frame: During the intraoperative ]\n\nComplications encountered during the prodecure""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Short term complications\n[ Time Frame: Within 48 hours after operation ]\n\nComplications within 48 hours after operation""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Late complications\n[ Time Frame: After 48 hours ]\n\nComplications occuring after 48 hours""}]","[{""label"":""Study Officials:"",""content"":""Achim Schneider, MD, MPH\nStudy Director\nCharité University Hospital Berlin, Germany""}]","[{""label"":""Sponsor:"",""content"":""Charite University, Berlin, Germany""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Giuseppe Vercellino\n\nOfficial Title: MD\nAffiliation: Charite University, Berlin, Germany""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01516827,1,5,2012-01-19,Not yet recruiting,2012-02-01,2014-07-01,Anticipated,150,Anticipated,7,14,All,NA,No,"[""Inclusion Criteria:\n\nAge 7-14 years\nExposure to a traumatic event (index trauma) after the age of 3 years, at least 3 months before assessment\n≥35 points on the Clinician -Administered PTSD Scale for Children and Adolescents (CAPS-CA) total symptom severity score and at least one symptom per PTSD cluster related to the index trauma according to DSM IV diagnostic criteria\nPTSD should be the main mental health problem, patients with co-morbid mental disorders are included\nNo major brain injury of the child due to the traumatic event (Glasgow Coma Scale <9 points at primary medical examination)\nCo-operation of at least one non-offending primary caregiver (improves treatment outcome)\nLiving within reasonable distance (max 1 hour of travel) to the treatment center to allow treatment on a weekly basis (feasibility)\n\nExclusion Criteria:\n\nPsychosis\nAcute suicidality""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS-PL)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nchange in co-morbid psychiatric disorders""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nPost-traumatic stress symptoms""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nAnxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nDepression""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nGeneral Psychopathology""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nQuality of Life""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related Cognitions (Child)""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related cognitions (Parent)""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: PTSD""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental Symptoms: Depression""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: Anxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""14."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""15."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""16."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change rom Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""17."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""18."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""19."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""20."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""21."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""22."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""23."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""24."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""25."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""26."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""27."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""28."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""29."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""30."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""31."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""32."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""33."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""34."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""35."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""36."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""37."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""38."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""39."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""40."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""41."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""42."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""43."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""44."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""45."",""content"":""Change from baselinein Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 6 monts post-treatment ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""46."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from baseline at 12 months post-treatment ]\n\nSymptom severity score""}]","[{""label"":""Central Contact Person:"",""content"":""Lutz Goldbeck, Prof.\nEmail: TCT.KJP@uniklinik-ulm.de""},{""label"":""Study Officials:"",""content"":""Lutz Goldbeck, Ph.D.\nPrincipal Investigator\nUniversity Ulm""}]","[{""label"":""Sponsor:"",""content"":""University of Ulm""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Lutz Goldbeck\n\nOfficial Title: Head of Section for Psychotherapy Re-search and Behavioural Medicine\nAffiliation: University of Ulm""},{""label"":""Collaborators:"",""content"":""Funding: Federal Ministry of Eduaction and Research""}]"
NCT01516827,2,5,2014-06-06,Recruiting,2012-02-01,2014-09-01,Anticipated,150,Anticipated,7,16,All,NA,No,"[""Inclusion Criteria:\n\nAge 7-16 years\nExposure to a traumatic event (index trauma) after the age of 3 years, at least 3 months before assessment\n≥35 points on the Clinician -Administered PTSD Scale for Children and Adolescents (CAPS-CA) total symptom severity score and at least one symptom per PTSD cluster related to the index trauma according to DSM IV diagnostic criteria\nPTSD should be the main mental health problem, patients with co-morbid mental disorders are included\nNo major brain injury of the child due to the traumatic event (Glasgow Coma Scale <9 points at primary medical examination)\nCo-operation of at least one non-offending primary caregiver (improves treatment outcome)\nLiving within reasonable distance (max 1 hour of travel) to the treatment center to allow treatment on a weekly basis (feasibility)\n\nExclusion Criteria:\n\nPsychosis\nAcute suicidality\nPsychopharmacological medication started or changed up to 6 weeks before first assessment""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS-PL)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nchange in co-morbid psychiatric disorders""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nPost-traumatic stress symptoms""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nAnxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nDepression""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nGeneral Psychopathology""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nQuality of Life""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related Cognitions (Child)""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related cognitions (Parent)""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: PTSD""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental Symptoms: Depression""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: Anxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""14."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""15."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""16."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change rom Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""17."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""18."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""19."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""20."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""21."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""22."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""23."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""24."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""25."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""26."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""27."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""28."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""29."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""30."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""31."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""32."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""33."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""34."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""35."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""36."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""37."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""38."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""39."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""40."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""41."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""42."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""43."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""44."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""45."",""content"":""Change from baselinein Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 6 monts post-treatment ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""46."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from baseline at 12 months post-treatment ]\n\nSymptom severity score""}]","[{""label"":""Central Contact Person:"",""content"":""Lutz Goldbeck, Prof.\nEmail: TCT.KJP@uniklinik-ulm.de""},{""label"":""Study Officials:"",""content"":""Lutz Goldbeck, Ph.D.\nPrincipal Investigator\nUniversity Ulm""}]","[{""label"":""Sponsor:"",""content"":""University of Ulm""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Lutz Goldbeck\n\nOfficial Title: Head of Section for Psychotherapy Re-search and Behavioural Medicine\nAffiliation: University of Ulm""},{""label"":""Collaborators:"",""content"":""Funding: Federal Ministry of Eduaction and Research""}]"
NCT01516827,3,5,2015-08-25,"Active, not recruiting",2012-02-01,2016-05-01,Anticipated,150,Anticipated,7,16,All,NA,No,"[""Inclusion Criteria:\n\nAge 7-16 years\nExposure to a traumatic event (index trauma) after the age of 3 years, at least 3 months before assessment\n≥35 points on the Clinician -Administered PTSD Scale for Children and Adolescents (CAPS-CA) total symptom severity score and at least one symptom per PTSD cluster related to the index trauma according to DSM IV diagnostic criteria\nPTSD should be the main mental health problem, patients with co-morbid mental disorders are included\nNo major brain injury of the child due to the traumatic event (Glasgow Coma Scale <9 points at primary medical examination)\nCo-operation of at least one non-offending primary caregiver (improves treatment outcome)\nLiving within reasonable distance (max 1 hour of travel) to the treatment center to allow treatment on a weekly basis (feasibility)\n\nExclusion Criteria:\n\nPsychosis\nAcute suicidality\nPsychopharmacological medication started or changed up to 6 weeks before first assessment""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS-PL)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nchange in co-morbid psychiatric disorders""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nPost-traumatic stress symptoms""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nAnxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nDepression""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nGeneral Psychopathology""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nQuality of Life""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related Cognitions (Child)""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related cognitions (Parent)""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: PTSD""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental Symptoms: Depression""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: Anxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""14."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""15."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""16."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change rom Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""17."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""18."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""19."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""20."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""21."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""22."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""23."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""24."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""25."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""26."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""27."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""28."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""29."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""30."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""31."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""32."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""33."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""34."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""35."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""36."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""37."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""38."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""39."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""40."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""41."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""42."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""43."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""44."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""45."",""content"":""Change from baselinein Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 6 monts post-treatment ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""46."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from baseline at 12 months post-treatment ]\n\nSymptom severity score""}]","[{""label"":""Study Officials:"",""content"":""Lutz Goldbeck, Ph.D.\nPrincipal Investigator\nUniversity Ulm""}]","[{""label"":""Sponsor:"",""content"":""University of Ulm""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Lutz Goldbeck\n\nOfficial Title: Head of Section for Psychotherapy Re-search and Behavioural Medicine\nAffiliation: University of Ulm""},{""label"":""Collaborators:"",""content"":""German Federal Ministry of Education and Research""}]"
NCT01516827,4,5,2016-07-11,Completed,2012-02-01,2016-06-01,Actual,159,Actual,7,16,All,NA,No,"[""Inclusion Criteria:\n\nAge 7-16 years\nExposure to a traumatic event (index trauma) after the age of 3 years, at least 3 months before assessment\n≥35 points on the Clinician -Administered PTSD Scale for Children and Adolescents (CAPS-CA) total symptom severity score and at least one symptom per PTSD cluster related to the index trauma according to DSM IV diagnostic criteria\nPTSD should be the main mental health problem, patients with co-morbid mental disorders are included\nNo major brain injury of the child due to the traumatic event (Glasgow Coma Scale <9 points at primary medical examination)\nCo-operation of at least one non-offending primary caregiver (improves treatment outcome)\nLiving within reasonable distance (max 1 hour of travel) to the treatment center to allow treatment on a weekly basis (feasibility)\n\nExclusion Criteria:\n\nPsychosis\nAcute suicidality\nPsychopharmacological medication started or changed up to 6 weeks before first assessment""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS-PL)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nchange in co-morbid psychiatric disorders""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nPost-traumatic stress symptoms""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nAnxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nDepression""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nGeneral Psychopathology""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nQuality of Life""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related Cognitions (Child)""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related cognitions (Parent)""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: PTSD""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental Symptoms: Depression""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: Anxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""14."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""15."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""16."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change rom Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""17."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""18."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""19."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""20."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""21."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""22."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""23."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""24."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""25."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""26."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""27."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""28."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""29."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""30."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""31."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""32."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""33."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""34."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""35."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""36."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""37."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""38."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""39."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""40."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""41."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""42."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""43."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""44."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""45."",""content"":""Change from baselinein Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 6 monts post-treatment ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""46."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from baseline at 12 months post-treatment ]\n\nSymptom severity score""}]","[{""label"":""Study Officials:"",""content"":""Lutz Goldbeck, Ph.D.\nPrincipal Investigator\nUniversity Ulm""}]","[{""label"":""Sponsor:"",""content"":""University of Ulm""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Lutz Goldbeck\n\nOfficial Title: Head of Section for Psychotherapy Re-search and Behavioural Medicine\nAffiliation: University of Ulm""},{""label"":""Collaborators:"",""content"":""German Federal Ministry of Education and Research""}]"
NCT01516827,5,5,2017-10-25,Completed,2012-02-01,2016-06-01,Actual,159,Actual,7,16,All,NA,No,"[""Inclusion Criteria:\n\nAge 7-16 years\nExposure to a traumatic event (index trauma) after the age of 3 years, at least 3 months before assessment\n≥35 points on the Clinician -Administered PTSD Scale for Children and Adolescents (CAPS-CA) total symptom severity score and at least one symptom per PTSD cluster related to the index trauma according to DSM IV diagnostic criteria\nPTSD should be the main mental health problem, patients with co-morbid mental disorders are included\nNo major brain injury of the child due to the traumatic event (Glasgow Coma Scale <9 points at primary medical examination)\nCo-operation of at least one non-offending primary caregiver (improves treatment outcome)\nLiving within reasonable distance (max 1 hour of travel) to the treatment center to allow treatment on a weekly basis (feasibility)\n\nExclusion Criteria:\n\nPsychosis\nAcute suicidality\nPsychopharmacological medication started or changed up to 6 weeks before first assessment""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS-PL)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nchange in co-morbid psychiatric disorders""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nPost-traumatic stress symptoms""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nAnxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nDepression""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nGeneral Psychopathology""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nQuality of Life""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related Cognitions (Child)""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nTrauma-related cognitions (Parent)""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: PTSD""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental Symptoms: Depression""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 8 weeks (=mid-treatment) ]\n\nParental symptoms: Anxiety""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""14."",""content"":""Change from Baseline in Children's Global Assessment Scale (CGAS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]\n\nGlobal impairment""},{""section"":""Secondary Outcome Measures:"",""label"":""15."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""16."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change rom Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""17."",""content"":""Change from Baseline in UCLA PTSD Reaction Index (self-report and caregiver report)\n[ Time Frame: Change from baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""18."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""19."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""20."",""content"":""Change from Baseline in Self-report for childhood anxiety related disorders (SCARED; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""21."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""22."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""23."",""content"":""Change from Baseline in Children's Depression Inventory (CDI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""24."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""25."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""26."",""content"":""Change from Baseline in Child Behavior Checklist (CBCL 4/18)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""27."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""28."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""29."",""content"":""Change from Baseline in Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK; Self-report and caregiver report)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""30."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""31."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""32."",""content"":""Change from Baseline in Child Post Traumatic Cognitions Inventory (CPTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""33."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""34."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""35."",""content"":""Change from Baseline in The Posttraumatic Cognitions Inventory (PTCI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""36."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""37."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""38."",""content"":""Change from Baseline in Posttraumatic Diagnostic Scale (PDS)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""39."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""40."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""41."",""content"":""Change from Baseline in Beck Depression Inventory (BDI-II)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""42."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 16 weeks (=end of treatment) ]""},{""section"":""Secondary Outcome Measures:"",""label"":""43."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 6 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""44."",""content"":""Change from Baseline in State-Trait-Anxiety-Inventory (STAI)\n[ Time Frame: Change from Baseline at 12 months post-treatment ]""},{""section"":""Secondary Outcome Measures:"",""label"":""45."",""content"":""Change from baselinein Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from Baseline at 6 monts post-treatment ]\n\nSymptom severity score""},{""section"":""Secondary Outcome Measures:"",""label"":""46."",""content"":""Change from Baseline in Clinician-Administered PTSD Scale for Children and Adolescents (CAPS-CA)\n[ Time Frame: Change from baseline at 12 months post-treatment ]\n\nSymptom severity score""}]","[{""label"":""Study Officials:"",""content"":""Lutz Goldbeck, Ph.D.\nPrincipal Investigator\nUniversity Ulm""}]","[{""label"":""Sponsor:"",""content"":""University of Ulm""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Lutz Goldbeck\n\nOfficial Title: Head of Section for Psychotherapy Re-search and Behavioural Medicine\nAffiliation: University of Ulm""},{""label"":""Collaborators:"",""content"":""German Federal Ministry of Education and Research""}]"
NCT01651832,1,4,2012-07-25,Recruiting,2012-07-01,2014-10-01,Anticipated,700,Anticipated,18,85,All,NA,No,"[""Inclusion Criteria:\n\ncolorectal carcinoma (ICD-10: C18, C19, C20)\nindication for adjuvant chemo therapy following S3-Guideline on colorectal Cancer or physician-directed\nliving in Saxony-Anhalt\nECOG-Performance Status <3\nprospective further life expectancy of more than three months\n\nExclusion Criteria:\n\nunabled to read oder understand german properly\nany contra-indication for adjuvant therapy as described in the S3-Guideline such as inadequate liver, bone marrow, and kidney function or coronary heart disease (NYHA III-IV).""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""disease-free survival\n[ Time Frame: 8 month after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Health-related Quality of Life\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the EORTC QLQ-C30 & CR-29""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""symptom burden\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the M.D. Anderson Symptom inventory""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Distress\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Distress-Thermometer""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""supportive care needs\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Supportive Needs Quastionaire-37 (FU-T)""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Quality of inpatient care\n[ Time Frame: at Baseline ]\n\nusing the EORTC INPATSAT-32""}]","[{""label"":""Central Contact Person:"",""content"":""Alexander Bauer, Dr.\nTelephone: +49 345 557-4124\nEmail: alexander.bauer@medizin.uni-halle.de""},{""label"":""Central Contact Backup:"",""content"":""Margarete Landenberger, Prof. Dr. phil. habil.\nTelephone: +49 345 557-1220\nEmail: margarete.landenberger@medizin.uni-halle.de""},{""label"":""Study Officials:"",""content"":""Margarete Landenberger, Prof. Dr.\nStudy Director\nMartin-Luther-University Halle-Wittenberg, Medical Faculty, Institute for Health and Nursing Science""}]","[{""label"":""Sponsor:"",""content"":""Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Alexander Bauer\n\nOfficial Title: Scientific Research Fellow\nAffiliation: Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01651832,2,4,2013-04-18,Recruiting,2012-07-01,2014-10-01,Anticipated,700,Anticipated,18,85,All,NA,No,"[""Inclusion Criteria:\n\ncolorectal carcinoma (ICD-10: C18, C19, C20)\nindication for adjuvant chemo therapy following S3-Guideline on colorectal Cancer or physician-directed\nliving in Saxony-Anhalt\nECOG-Performance Status <3\nprospective further life expectancy of more than three months\n\nExclusion Criteria:\n\nunabled to read oder understand german properly\nany contra-indication for adjuvant therapy as described in the S3-Guideline such as inadequate liver, bone marrow, and kidney function or coronary heart disease (NYHA III-IV).""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""disease-free survival\n[ Time Frame: 8 month after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Health-related Quality of Life\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the EORTC QLQ-C30 & CR-29""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""symptom burden\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the M.D. Anderson Symptom inventory""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Distress\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Distress-Thermometer""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""supportive care needs\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Supportive Needs Quastionaire-37 (FU-T)""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Quality of inpatient care\n[ Time Frame: at Baseline ]\n\nusing the EORTC INPATSAT-32""}]","[{""label"":""Central Contact Person:"",""content"":""Alexander Bauer, Dr.\nTelephone: +49 345 557-4124\nEmail: alexander.bauer@medizin.uni-halle.de""},{""label"":""Central Contact Backup:"",""content"":""Margarete Landenberger, Prof. Dr. phil. habil.\nTelephone: +49 345 557-1220\nEmail: margarete.landenberger@medizin.uni-halle.de""},{""label"":""Study Officials:"",""content"":""Margarete Landenberger, Prof. Dr.\nStudy Director\nMartin-Luther-University Halle-Wittenberg, Medical Faculty, Institute for Health and Nursing Science""}]","[{""label"":""Sponsor:"",""content"":""Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Alexander Bauer\n\nOfficial Title: Scientific Research Fellow\nAffiliation: Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01651832,3,4,2014-12-01,Recruiting,2012-07-01,2015-12-01,Anticipated,700,Anticipated,18,85,All,NA,No,"[""Inclusion Criteria:\n\ncolorectal carcinoma (ICD-10: C18, C19, C20)\nindication for adjuvant chemo therapy following S3-Guideline on colorectal Cancer or physician-directed\nliving in Saxony-Anhalt\nECOG-Performance Status <3\nprospective further life expectancy of more than three months\n\nExclusion Criteria:\n\nunable to read or understand German properly\nany contra-indication for adjuvant therapy as described in the S3-Guideline such as inadequate liver, bone marrow, and kidney function or coronary heart disease (NYHA III-IV).""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""disease-free survival\n[ Time Frame: 8 month after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Health-related Quality of Life\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the EORTC QLQ-C30 & CR-29""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""symptom burden\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the M.D. Anderson Symptom inventory""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Distress\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Distress-Thermometer""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""supportive care needs\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Supportive Needs Questionnaire-37 (FU-T)""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Quality of inpatient care\n[ Time Frame: at Baseline ]\n\nusing the EORTC INPATSAT-32""}]","[{""label"":""Central Contact Person:"",""content"":""Alexander Bauer, Dr.\nTelephone: +49 345 557-4124\nEmail: alexander.bauer@medizin.uni-halle.de""},{""label"":""Central Contact Backup:"",""content"":""Margarete Landenberger, Prof. Dr. phil. habil.\nTelephone: +49 345 557-1220\nEmail: margarete.landenberger@medizin.uni-halle.de""},{""label"":""Study Officials:"",""content"":""Margarete Landenberger, Prof. Dr.\nStudy Director\nMartin-Luther-University Halle-Wittenberg, Medical Faculty, Institute for Health and Nursing Science""}]","[{""label"":""Sponsor:"",""content"":""Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Alexander Bauer\n\nOfficial Title: Scientific Research Fellow\nAffiliation: Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01651832,4,4,2016-10-24,Completed,2012-07-01,2015-12-01,Actual,261,Actual,18,85,All,NA,No,"[""Inclusion Criteria:\n\ncolorectal carcinoma (ICD-10: C18, C19, C20)\nindication for adjuvant chemo therapy following S3-Guideline on colorectal Cancer or physician-directed\nliving in Saxony-Anhalt\nECOG-Performance Status <3\nprospective further life expectancy of more than three months\n\nExclusion Criteria:\n\nunable to read or understand German properly\nany contra-indication for adjuvant therapy as described in the S3-Guideline such as inadequate liver, bone marrow, and kidney function or coronary heart disease (NYHA III-IV).""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""proportion of eligible patients undergoing adjuvant chemo therapy\n[ Time Frame: 8 weeks after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""disease-free survival\n[ Time Frame: 8 month after hospital discharge/ chrirurgical resection ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Health-related Quality of Life\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the EORTC QLQ-C30 & CR-29""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""symptom burden\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the M.D. Anderson Symptom inventory""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Distress\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Distress-Thermometer""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""supportive care needs\n[ Time Frame: 8 weeks & 8 month after hospital discharge/ chrirurgical resection ]\n\nusing the Supportive Needs Questionnaire-37 (FU-T)""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Quality of inpatient care\n[ Time Frame: at Baseline ]\n\nusing the EORTC INPATSAT-32""}]","[{""label"":""Study Officials:"",""content"":""Margarete Landenberger, Prof. Dr.\nStudy Director\nMartin-Luther-University Halle-Wittenberg, Medical Faculty, Institute for Health and Nursing Science""}]","[{""label"":""Sponsor:"",""content"":""Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Alexander Bauer\n\nOfficial Title: Scientific Research Fellow\nAffiliation: Martin-Luther-Universität Halle-Wittenberg""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,1,11,2012-02-29,Not yet recruiting,2012-07-01,2014-07-01,Anticipated,208,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-TNFs. Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin [hCG]). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAST and ALT ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; HSA (Human Serum Albumin); DMEM (Dulbecco Modified Eagle's Medium); materials of bovin origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCDAI score""}]",[],"[{""label"":""Sponsor:"",""content"":""Cellerix""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,2,11,2012-12-11,Recruiting,2012-07-01,2014-07-01,Anticipated,208,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""}]","[{""label"":""Central Contact Person:"",""content"":""Lydia Dorrego, Pharmacy\nEmail: lydia.dorrego@tigenix.com""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Walter Reinisch, Proffesor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, Proffesor\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, MD\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Proffesor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Proffesor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, MD\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Proffesor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Proffesor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Geert D'Haens, Proffesor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""}]","[{""label"":""Sponsor:"",""content"":""Cellerix""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,3,11,2013-02-07,Recruiting,2012-07-01,2014-07-01,Anticipated,208,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""}]","[{""label"":""Central Contact Person:"",""content"":""Lydia Dorrego, Pharmacy\nEmail: lydia.dorrego@tigenix.com""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Walter Reinisch, Proffesor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, Proffesor\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, MD\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Proffesor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Proffesor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, MD\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Proffesor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Proffesor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Geert D'Haens, Proffesor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""}]","[{""label"":""Sponsor:"",""content"":""Cellerix""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,4,11,2013-03-05,Recruiting,2012-07-01,2014-07-01,Anticipated,208,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""}]","[{""label"":""Central Contact Person:"",""content"":""Lydia Dorrego, Pharmacy\nEmail: lydia.dorrego@tigenix.com""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Walter Reinisch, Proffesor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, Proffesor\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, MD\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Proffesor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Proffesor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, MD\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Proffesor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Proffesor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Geert D'Haens, Proffesor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,5,11,2014-01-03,Recruiting,2012-07-01,2014-07-01,Anticipated,208,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 and 52 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment\n[ Time Frame: 52 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).\nRemission rate of perianal fistulising Crohn's disease at week 52 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 52, confirmed by MRI as abscence of collections > 2 cm of the treated perianal fistulas at 52 weeks (central blind assessment).""}]","[{""label"":""Central Contact Person:"",""content"":""Lydia Dorrego, Pharmacy\nEmail: lydia.dorrego@tigenix.com""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Walter Reinisch, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, Professor\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, MD\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, MD\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, MD\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Jean-Marie Reimund, Professor\nPrincipal Investigator\nUniversity Hospital, Bordeaux""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Yehuda Chowers, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,6,11,2014-03-10,Recruiting,2012-07-01,2015-01-01,Anticipated,208,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 and 52 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment\n[ Time Frame: 52 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).\nRemission rate of perianal fistulising Crohn's disease at week 52 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 52, confirmed by MRI as abscence of collections > 2 cm of the treated perianal fistulas at 52 weeks (central blind assessment).""}]","[{""label"":""Central Contact Person:"",""content"":""Lydia Dorrego, Pharmacy\nEmail: lydia.dorrego@tigenix.com""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Lili Kazemi-Shirazi, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, Professor\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, MD\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, MD\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, MD\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Stéphanie Viennot, MD\nPrincipal Investigator\nUniversity Hospital, Caen""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Matti Waterman, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""},{""label"":""Study Officials:"",""content"":""Herbert Tilg, Professor\nPrincipal Investigator\nUniv.-Klinik Innsbruck""},{""label"":""Study Officials:"",""content"":""Lennard Gilissen, MD\nPrincipal Investigator\nCatharina Ziekenhuis Eindhoven""},{""label"":""Study Officials:"",""content"":""Carlos Pastor, MD\nPrincipal Investigator\nInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,7,11,2014-03-11,Recruiting,2012-07-01,2015-01-01,Anticipated,278,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 and 52 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment\n[ Time Frame: 52 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).\nRemission rate of perianal fistulising Crohn's disease at week 52 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 52, confirmed by MRI as abscence of collections > 2 cm of the treated perianal fistulas at 52 weeks (central blind assessment).""}]","[{""label"":""Central Contact Person:"",""content"":""María Pascual\nEmail: maria.pascual@tigenix.com""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Lili Kazemi-Shirazi, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, MD\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, Professor\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, Professor\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, Professor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Stéphanie Viennot, MD\nPrincipal Investigator\nUniversity Hospital, Caen""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Matti Waterman, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""},{""label"":""Study Officials:"",""content"":""Herbert Tilg, Professor\nPrincipal Investigator\nUniv.-Klinik Innsbruck""},{""label"":""Study Officials:"",""content"":""Lennard Gilissen, MD\nPrincipal Investigator\nCatharina Ziekenhuis Eindhoven""},{""label"":""Study Officials:"",""content"":""Carlos Pastor, MD\nPrincipal Investigator\nInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz""},{""label"":""Study Officials:"",""content"":""Wolfgang Kruis, Professor\nPrincipal Investigator\nEvangelisches Krankenhaus Kalk, Köln""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,8,11,2014-12-11,"Active, not recruiting",2012-07-01,2016-01-01,Anticipated,278,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment\n[ Time Frame: 24 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Safety Assessment\n[ Time Frame: 24 and 52 weeks ]\n\n\nAdverse events\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)\nCrohn's disease activity index (CDAI) score""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment\n[ Time Frame: 52 weeks ]\n\n\nResponse, defined as closure of at least 50% of all external openings that were draining at baseline.\nTime to remission, (first visit with closure of all external openings that were draining at baseline, as clinically assessed).\nTime to response (first visit with closure of at least 50% of all external openings that were draining at baseline, as clinically assessed).\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI).\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ).\nRemission rate of perianal fistulising Crohn's disease at week 52 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 52, confirmed by MRI as abscence of collections > 2 cm of the treated perianal fistulas at 52 weeks (central blind assessment).""}]","[{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Lili Kazemi-Shirazi, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, MD\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, Professor\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, Professor\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, Professor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Stéphanie Viennot, MD\nPrincipal Investigator\nUniversity Hospital, Caen""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Matti Waterman, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""},{""label"":""Study Officials:"",""content"":""Herbert Tilg, Professor\nPrincipal Investigator\nUniv.-Klinik Innsbruck""},{""label"":""Study Officials:"",""content"":""Lennard Gilissen, MD\nPrincipal Investigator\nCatharina Ziekenhuis Eindhoven""},{""label"":""Study Officials:"",""content"":""Carlos Pastor, MD\nPrincipal Investigator\nInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz""},{""label"":""Study Officials:"",""content"":""Wolfgang Kruis, Professor\nPrincipal Investigator\nEvangelisches Krankenhaus Kalk, Köln""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,9,11,2015-11-25,"Active, not recruiting",2012-07-01,2015-07-01,Actual,278,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment by week 24\n[ Time Frame: 24 weeks ]\n\n\nClinical Remission (CR) defined as closure of all treated EO that were draining at baseline despite gentle finger compression, as clinically assessed\nResponse defined as closure of at least 50% of all treated EO that were draining at baseline, as clinically assessed\nTime to Clinical Remission (time from treatment start to 1st visit with closure of all treated EO as described above)\nTime to Response (time from treatment start to 1st visit with closure of at least 50% of all treated EO as described above)\nRelapse defined, in patients with CR at previous visit, as reopening of any of the treated EO with active drainage, or the development of a perianal collection > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI\nTime to Relapse in patients with CR (time from CR to 1st visit with reopening of any of the treated EO as described above)\nSeverity of the perianal CD, assessed with the PDAI\nQoL assessed by IBDQ\nCDAI score\nVan Assche""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Efficacy Assessment by week 52\n[ Time Frame: 52 weeks ]\n\n\nCombined Remission of perianal fistulising Crohn's disease at week 52 (as defined for week 24)\nClinical Remission defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression, as clinically assessed at week 52\nResponse defined as closure of at least 50% of all treated external openings that were draining at baseline, as clinically assessed at week 52\nTime to Combined Remission by week 52 (as defined for week 24)\nTime to Clinical Remission by week 52 (as defined for week 24)\nTime to Response by week 52 (as defined for week 24)\nRelapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)\nTime to Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)\nSeverity of the perianal Crohn's disease up to week 52 assessed PDAI\nQoL up to week 52 by the IBDQ\nCDAI score up to week 52\nVan Assche score up to week 52""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment by week 104\n[ Time Frame: 104 Weeks ]\n\n\nClinical Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings that were draining at baseline despite gentle finger compression at week 104\nRelapse by week 104 in patients with Combined Remission at week 52, defined as reopening of any of the treated external openings with active drainage as clinically assessed\nTime to Relapse by week 104 in patients with Combined Remission at week 52 (defined as time from Combined Remission to first visit with reopening of any of the treated external openings with active drainage as clinically assessed)\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI) up to week 104\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) up to week 104\nCDAI score up to week 104""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Safety analysis throughout the study:\n[ Time Frame: week 24, 52 and 104 ]\n\n\nAdverse events including: Treatment emergent Adverse Events (TEAEs), TEAEs related to study treatment, Treatment emergent Serious Adverse Events (TESAEs), TESAEs related to study treatment, TEAEs leading to study withdrawal, adverse events related to surgical procedure(s) to provide study treatment, deaths Only SAEs will be reported during the 2nd follow-up period between week 52 and week 104.\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)""}]","[{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Lili Kazemi-Shirazi, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, MD\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, Professor\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, Professor\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, Professor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Stéphanie Viennot, MD\nPrincipal Investigator\nUniversity Hospital, Caen""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Matti Waterman, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""},{""label"":""Study Officials:"",""content"":""Herbert Tilg, Professor\nPrincipal Investigator\nUniv.-Klinik Innsbruck""},{""label"":""Study Officials:"",""content"":""Lennard Gilissen, MD\nPrincipal Investigator\nCatharina Ziekenhuis Eindhoven""},{""label"":""Study Officials:"",""content"":""Carlos Pastor, MD\nPrincipal Investigator\nInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz""},{""label"":""Study Officials:"",""content"":""Wolfgang Kruis, Professor\nPrincipal Investigator\nEvangelisches Krankenhaus Kalk, Köln""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,10,11,2016-11-30,"Active, not recruiting",2012-07-01,2015-07-01,Actual,278,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment by week 24\n[ Time Frame: 24 weeks ]\n\n\nClinical Remission (CR) defined as closure of all treated EO that were draining at baseline despite gentle finger compression, as clinically assessed\nResponse defined as closure of at least 50% of all treated EO that were draining at baseline, as clinically assessed\nTime to Clinical Remission (time from treatment start to 1st visit with closure of all treated EO as described above)\nTime to Response (time from treatment start to 1st visit with closure of at least 50% of all treated EO as described above)\nRelapse defined, in patients with CR at previous visit, as reopening of any of the treated EO with active drainage, or the development of a perianal collection > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI\nTime to Relapse in patients with CR (time from CR to 1st visit with reopening of any of the treated EO as described above)\nSeverity of the perianal CD, assessed with the PDAI\nQoL assessed by IBDQ\nCDAI score\nVan Assche""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Efficacy Assessment by week 52\n[ Time Frame: 52 weeks ]\n\n\nCombined Remission of perianal fistulising Crohn's disease at week 52 (as defined for week 24)\nClinical Remission defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression, as clinically assessed at week 52\nResponse defined as closure of at least 50% of all treated external openings that were draining at baseline, as clinically assessed at week 52\nTime to Combined Remission by week 52 (as defined for week 24)\nTime to Clinical Remission by week 52 (as defined for week 24)\nTime to Response by week 52 (as defined for week 24)\nRelapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)\nTime to Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)\nSeverity of the perianal Crohn's disease up to week 52 assessed PDAI\nQoL up to week 52 by the IBDQ\nCDAI score up to week 52\nVan Assche score up to week 52""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment by week 104\n[ Time Frame: 104 Weeks ]\n\n\nClinical Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings that were draining at baseline despite gentle finger compression at week 104\nRelapse by week 104 in patients with Combined Remission at week 52, defined as reopening of any of the treated external openings with active drainage as clinically assessed\nTime to Relapse by week 104 in patients with Combined Remission at week 52 (defined as time from Combined Remission to first visit with reopening of any of the treated external openings with active drainage as clinically assessed)\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI) up to week 104\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) up to week 104\nCDAI score up to week 104""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Safety analysis throughout the study:\n[ Time Frame: week 24, 52 and 104 ]\n\n\nAdverse events including: Treatment emergent Adverse Events (TEAEs), TEAEs related to study treatment, Treatment emergent Serious Adverse Events (TESAEs), TESAEs related to study treatment, TEAEs leading to study withdrawal, adverse events related to surgical procedure(s) to provide study treatment, deaths Only SAEs will be reported during the 2nd follow-up period between week 52 and week 104.\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)""}]","[{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Lili Kazemi-Shirazi, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, MD\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, Professor\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, Professor\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, Professor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Stéphanie Viennot, MD\nPrincipal Investigator\nUniversity Hospital, Caen""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Matti Waterman, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""},{""label"":""Study Officials:"",""content"":""Herbert Tilg, Professor\nPrincipal Investigator\nUniv.-Klinik Innsbruck""},{""label"":""Study Officials:"",""content"":""Lennard Gilissen, MD\nPrincipal Investigator\nCatharina Ziekenhuis Eindhoven""},{""label"":""Study Officials:"",""content"":""Carlos Pastor, MD\nPrincipal Investigator\nInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz""},{""label"":""Study Officials:"",""content"":""Wolfgang Kruis, Professor\nPrincipal Investigator\nEvangelisches Krankenhaus Kalk, Köln""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01541579,11,11,2019-11-27,Completed,2012-07-01,2015-07-01,Actual,278,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nThe reference population will consist of patients with perianal fistulising Crohn´s disease refractory to at least one of the following treatments: antibiotics, immunosuppressants or anti-tumor necrosis factor (TNF). Naïve patients are excluded, and those patients refractory to antibiotics will represent less than 25% of the total recruited patients.\n\nAll of them must comply with the following inclusion criteria:\n\nSigned informed consent.\nPatients with Crohn's Disease (CD) diagnosed at least 6 months earlier in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria.\nPresence of complex perianal fistulas with a maximum of 2 fistulas (internal openings) and a maximum of 3 external openings, assessed by clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the inclusion. A complex perianal fistula is defined as a fistula that met one or more of the following criteria during its evolution:\nHigh inter-sphincteric, trans-sphincteric, extra-sphincteric or supra-sphincteric.\nPresence of ≥ 2 external openings (tracts).\nAssociated collections\nNon-active or mildly active luminal CD defined by a CDAI ≤ 220.\nPatients of either sex aged 18 years or older\nGood general state of health according to clinical history and a physical examination.\nFor women of a childbearing age, they must have negative serum or urine pregnancy test (sensitive to 25 IU human chorionic gonadotropin (hCG)). Both men and women should use appropriate birth control methods defined by the investigator.\n\nExclusion Criteria:\n\nPresence of dominant luminal active Crohn's disease requiring immediate therapy.\nCDAI >220.\nConcomitant rectovaginal fistulas\nPatient naïve to specific treatment for perianal fistulising Crohn's disease including antibiotics\nPresence of an abscess or collections > 2 cm, unless resolved in the preparation procedure (week -3 to day 0).\nPresence of > 2 fistular lesions.\nPresence of > 3 external openings.\nRectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.\nPatient who underwent surgery for the fistula other than drainage or seton placement.\nPatient with diverting stomas\nPatient with ongoing steroid treatment or treated with steroids in the last 4 weeks\nRenal impairment defined by creatinine clearance below 60 ml/min calculated using Cockcroft-Gault formula or by serum creatinine ≥ 1.5 x upper limit of normality (ULN)\nHepatic impairment defined by both of the following laboratory ranges:\nTotal bilirubin ≥ 1.5 x ULN\nAspartate aminotransferase (AST) and alanine aminotransferase(ALT) ≥ 2.5 x ULN\nKnown history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion.\nMalignant tumour or patients with a prior history of any malignant tumour, including any type of fistula carcinoma.\nCurrent or recent history of abnormal, severe, progressive, uncontrolled hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease.\nCongenital or acquired immunodeficiencies.\nKnown allergies or hypersensitivity to antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast).\nContraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements or severe claustrophobia).\nMajor surgery or severe trauma within the previous 6 months.\nPregnant or breastfeeding women.\nPatients who do not wish to or cannot comply with study procedures.\nPatients currently receiving, or having received within 3 months prior to enrolment into this clinical study, any investigational drug.\nPatients previously treated with eASCs can not be enrol into this clinical study.\nSubjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.\nContraindication to the anaesthetic procedure.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Efficacy Assessment by week 24\n[ Time Frame: 24 weeks ]\n\n\nClinical Remission (CR) defined as closure of all treated EO that were draining at baseline despite gentle finger compression, as clinically assessed\nResponse defined as closure of at least 50% of all treated EO that were draining at baseline, as clinically assessed\nTime to Clinical Remission (time from treatment start to 1st visit with closure of all treated EO as described above)\nTime to Response (time from treatment start to 1st visit with closure of at least 50% of all treated EO as described above)\nRelapse defined, in patients with CR at previous visit, as reopening of any of the treated EO with active drainage, or the development of a perianal collection > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI\nTime to Relapse in patients with CR (time from CR to 1st visit with reopening of any of the treated EO as described above)\nSeverity of the perianal CD, assessed with the PDAI\nQoL assessed by IBDQ\nCDAI score\nVan Assche""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Efficacy Assessment by week 52\n[ Time Frame: 52 weeks ]\n\n\nCombined Remission of perianal fistulising Crohn's disease at week 52 (as defined for week 24)\nClinical Remission defined as the closure of all treated external openings that were draining at baseline despite gentle finger compression, as clinically assessed at week 52\nResponse defined as closure of at least 50% of all treated external openings that were draining at baseline, as clinically assessed at week 52\nTime to Combined Remission by week 52 (as defined for week 24)\nTime to Clinical Remission by week 52 (as defined for week 24)\nTime to Response by week 52 (as defined for week 24)\nRelapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)\nTime to Relapse by week 52 in patients with Combined Remission at week 24 (as defined for week 24)\nSeverity of the perianal Crohn's disease up to week 52 assessed PDAI\nQoL up to week 52 by the IBDQ\nCDAI score up to week 52\nVan Assche score up to week 52""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Efficacy Assessment by week 104\n[ Time Frame: 104 Weeks ]\n\n\nClinical Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings that were draining at baseline despite gentle finger compression at week 104\nRelapse by week 104 in patients with Combined Remission at week 52, defined as reopening of any of the treated external openings with active drainage as clinically assessed\nTime to Relapse by week 104 in patients with Combined Remission at week 52 (defined as time from Combined Remission to first visit with reopening of any of the treated external openings with active drainage as clinically assessed)\nSeverity of the perianal Crohn's disease, assessed with the Perianal Disease Activity Index (PDAI) up to week 104\nQuality of Life (QoL) assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ) up to week 104\nCDAI score up to week 104""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Safety analysis throughout the study:\n[ Time Frame: week 24, 52 and 104 ]\n\n\nAdverse events including: Treatment emergent Adverse Events (TEAEs), TEAEs related to study treatment, Treatment emergent Serious Adverse Events (TESAEs), TESAEs related to study treatment, TEAEs leading to study withdrawal, adverse events related to surgical procedure(s) to provide study treatment, deaths Only SAEs will be reported during the 2nd follow-up period between week 52 and week 104.\nPhysical examination\nVital signs\nLaboratory tests (biochemistry, haematology, urinalysis)""}]","[{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nStudy Chair\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Julian Panes, MD\nPrincipal Investigator\nHospital Clinic of Barcelona""},{""label"":""Study Officials:"",""content"":""Lili Kazemi-Shirazi, Professor\nPrincipal Investigator\nMedical University of Vienna""},{""label"":""Study Officials:"",""content"":""Karl Mrak, MD\nPrincipal Investigator\nKrankenhaus, St. Veit/Glan""},{""label"":""Study Officials:"",""content"":""Marc Ferrante, MD\nPrincipal Investigator\nUniversitaire Ziekenhuizen Leuven""},{""label"":""Study Officials:"",""content"":""Kurt Van der Speeten, MD\nPrincipal Investigator\nHospital Oost-Limburg, Genk""},{""label"":""Study Officials:"",""content"":""Danny de Looze, Professor\nPrincipal Investigator\nGent University Hospital""},{""label"":""Study Officials:"",""content"":""Filip Baert, MD\nPrincipal Investigator\nHospital Hartziekenhuis, Roeselare""},{""label"":""Study Officials:"",""content"":""Daniel C Baumgart, Professor\nPrincipal Investigator\nCharite University, Berlin, Germany""},{""label"":""Study Officials:"",""content"":""Axel Dignass, Professor\nPrincipal Investigator\nKilikum Frankfurt""},{""label"":""Study Officials:"",""content"":""Max Reinshagen, Professor\nPrincipal Investigator\nKinikum Braunschweig""},{""label"":""Study Officials:"",""content"":""Silvio Danese, MD\nPrincipal Investigator\nInstituto Clinico Humanitas IRCCS, Milano""},{""label"":""Study Officials:"",""content"":""Vito Annese, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria Careggi, Firenze""},{""label"":""Study Officials:"",""content"":""Anna Kohn, MD\nPrincipal Investigator\nAzienda Ospedaliera San Camillo-Forlanini, Rome""},{""label"":""Study Officials:"",""content"":""Alfredo Papa, MD\nPrincipal Investigator\nUniversità Cattolica del Sacro Cuore, Rome""},{""label"":""Study Officials:"",""content"":""Giacomo C Sturniolo, Professor\nPrincipal Investigator\nAzienda Ospedaliera di Padova""},{""label"":""Study Officials:"",""content"":""Andrea Belluzi, MD\nPrincipal Investigator\nAzienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi""},{""label"":""Study Officials:"",""content"":""Gabriele Riegler, Professor\nPrincipal Investigator\nUniversity of Campania \""Luigi Vanvitelli\""""},{""label"":""Study Officials:"",""content"":""Bas Oldenburg, MD\nPrincipal Investigator\nUMCU, Utrecht""},{""label"":""Study Officials:"",""content"":""Adriaan A van Bodegraven, MD\nPrincipal Investigator\nVU University Medical Center""},{""label"":""Study Officials:"",""content"":""Gigs van den Brink, Professor\nPrincipal Investigator\nAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)""},{""label"":""Study Officials:"",""content"":""María D Martín Arranz, MD\nPrincipal Investigator\nHospital Universitario La Paz""},{""label"":""Study Officials:"",""content"":""Jose M Gallardo Valverde, MD\nPrincipal Investigator\nHospital Universitario Reina Sofía, Cordoba""},{""label"":""Study Officials:"",""content"":""Javier Pérez Gisbert, MD\nPrincipal Investigator\nHospital La Princesa, Madrid""},{""label"":""Study Officials:"",""content"":""Belén Beltrán Niclós, MD\nPrincipal Investigator\nHospital Universitario La Fe""},{""label"":""Study Officials:"",""content"":""Carlos Taxonera Samsó, MD\nPrincipal Investigator\nHospital Clínico San Carlos, Madrid""},{""label"":""Study Officials:"",""content"":""Fernando de la Portilla de Juan, MD\nPrincipal Investigator\nHospital Virgen del Rocío, Seville""},{""label"":""Study Officials:"",""content"":""Ricardo Rada Morgades, MD\nPrincipal Investigator\nHospital Juan Ramón Jiménez, Huelva""},{""label"":""Study Officials:"",""content"":""Gonzalo Gómez Gómez, MD\nPrincipal Investigator\nHospital Universitario 12 de Octubre, Madrid""},{""label"":""Study Officials:"",""content"":""Daniel Carpio López, MD\nPrincipal Investigator\nHospital de Montecelo, Pontevedra""},{""label"":""Study Officials:"",""content"":""Xavier Cortés Rizo, MD\nPrincipal Investigator\nHospital de Sagunto, Valencia""},{""label"":""Study Officials:"",""content"":""Torsten Kucharzik, Professor\nPrincipal Investigator\nKlinikum Lüneburg""},{""label"":""Study Officials:"",""content"":""Andreas Sturm, Professor\nPrincipal Investigator\nKrakenhaus Walfriede, Berlin""},{""label"":""Study Officials:"",""content"":""Antonio López Sanromán, MD\nPrincipal Investigator\nHospital Universitario Ramon y Cajal""},{""label"":""Study Officials:"",""content"":""Joaquín Hinojosa de Val, MD\nPrincipal Investigator\nHospital de Manises, Valencia""},{""label"":""Study Officials:"",""content"":""Xavier González Argenté, MD\nPrincipal Investigator\nSon Espases, Palma de Mallorca""},{""label"":""Study Officials:"",""content"":""Maria Nachury, MD\nPrincipal Investigator\nCHRU de Lille""},{""label"":""Study Officials:"",""content"":""Frank Zerbib, MD\nPrincipal Investigator\nCHU Bordeaux""},{""label"":""Study Officials:"",""content"":""Stéphanie Viennot, MD\nPrincipal Investigator\nUniversity Hospital, Caen""},{""label"":""Study Officials:"",""content"":""Jean-Louis Dupas, MD\nPrincipal Investigator\nCentre Hospitalier Universitaire, Amiens""},{""label"":""Study Officials:"",""content"":""Jean-Charles Grimaud, MD\nPrincipal Investigator\nCHU de Marseille""},{""label"":""Study Officials:"",""content"":""Xavier Hebuterne, Professor\nPrincipal Investigator\nCentre Hospitalier Universitaire de Nice""},{""label"":""Study Officials:"",""content"":""Matthieu Allez, Professor\nPrincipal Investigator\nHôpital Saint Louis Paris""},{""label"":""Study Officials:"",""content"":""Yoram Bouhnik, MD\nPrincipal Investigator\nHôpital Beaujon, Clichy""},{""label"":""Study Officials:"",""content"":""Matti Waterman, MD\nPrincipal Investigator\nRambam MC, Haifa""},{""label"":""Study Officials:"",""content"":""Shomron Ben-Horin, MD\nPrincipal Investigator\nSheba MC, Tel Hashomer""},{""label"":""Study Officials:"",""content"":""Sigal Fishman, MD\nPrincipal Investigator\nTel Aviv Sourasky MC, Tel Aviv""},{""label"":""Study Officials:"",""content"":""Eran Goldin, Professor\nPrincipal Investigator\nSharee Zedek MC, Jerusalem""},{""label"":""Study Officials:"",""content"":""Irit Avni-Biron, MD\nPrincipal Investigator\nRabin MC, Petah Tikva""},{""label"":""Study Officials:"",""content"":""Herbert Tilg, Professor\nPrincipal Investigator\nUniv.-Klinik Innsbruck""},{""label"":""Study Officials:"",""content"":""Lennard Gilissen, MD\nPrincipal Investigator\nCatharina Ziekenhuis Eindhoven""},{""label"":""Study Officials:"",""content"":""Carlos Pastor, MD\nPrincipal Investigator\nInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz""},{""label"":""Study Officials:"",""content"":""Wolfgang Kruis, Professor\nPrincipal Investigator\nEvangelisches Krankenhaus Kalk, Köln""}]","[{""label"":""Sponsor:"",""content"":""Tigenix S.A.U.""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT02307396,1,3,2014-12-01,Recruiting,2014-11-01,2016-12-01,Anticipated,25,Anticipated,18,65,All,NA,No,"[""Inclusion Criteria:\n\nDiagnosis of schizophrenia or schizoaffective disorder\nThe participants have to be in remission for at least 3 years (i.e. no psychiatric hospitalisation) under a stable antipsychotic medication. Remission will be measured using the remission criteria by Andreasen et al. (2005) Score ≤3 for the items concerning psychosis of the \""Positive and Negative Syndrom Scale\"" (PANSS; Kay et al., 1987): \""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) and a score ≤3 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976)\nAble to give informed consent\n\nExclusion Criteria:\n\nActively suicidal\nSerious medical illnesses\nKnown non-complience concerning the medication\nMedication with clozapin\nMedication with antidepressants and mood stabilisors that were initiated during the last 6 weeks before study enrollment\nPatients with substance dependence other than nicotine or caffeine within 6 months prior to baseline\nUnability to give informed consent\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse\n[ Time Frame: Every 2 weeks up to 26 weeks ]\n\n\n\nThe criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:\n\nScore ≥4 (moderate) for at least two of the following PANSS-items :\n\n\""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) (PANSS; Kay et al., 1987)\n\nScore ≥4 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976b)""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Psychiatric rehospitalisation\n[ Time Frame: Every 2 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Totalscore of Positive and Negative Syndrome Scale (PANSS)\n[ Time Frame: Baseline, then every 4 weeks up to 26 weeks ]\n\nPANSS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Occurence of specific adverse effects (open interview)\n[ Time Frame: Baseline,then every 4 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Clinical Global Impression - Severity Scale (CGI-S)\n[ Time Frame: Baseline, then every 4 weeks up to 26 weeks ]\n\nCGI-I Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""\""Quality of life\"" measured by the questionnaire \""Subjective well-being under neuroleptics scale\"" (SW-N)\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nSW-N-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Status of occupation\n[ Time Frame: Baseline, and after 12 and 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Personal and Social Performance (Personal and Social Performance Scale [PSP])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nPSP-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Adherence/Attitude of patients towards medication (Medication Adherence Rating Scale [MARS])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nMARS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Drop-outs total and due to specific reasons\n[ Time Frame: Every 2 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Movement disorders (Abnormal Involuntary Movement Scale [AIMS])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nAIMS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Weight change\n[ Time Frame: Baseline, and after 12 and 26 weeks ]""}]","[{""label"":""Central Contact Person:"",""content"":""Stefan Leucht, Professor\nTelephone: +49 89 4140 Ext. 4249\nEmail: stefan.leucht@lrz.tum.de""},{""label"":""Central Contact Backup:"",""content"":""Maximilian Huhn, MD\nTelephone: +49 89 4140 Ext. 6466\nEmail: maximilian.huhn@lrz.tum.de""},{""label"":""Study Officials:"",""content"":""Stefan Leucht, Professor\nPrincipal Investigator\nKlinikum rechts der Isar""},{""label"":""Study Officials:"",""content"":""Markus Dold, MD\nPrincipal Investigator\nKlinikum rechts der Isar""}]","[{""label"":""Sponsor:"",""content"":""Technische Universität München""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT02307396,2,3,2016-02-29,"Active, not recruiting",2014-11-01,2016-05-01,Anticipated,25,Anticipated,18,65,All,NA,No,"[""Inclusion Criteria:\n\nDiagnosis of schizophrenia or schizoaffective disorder\nThe participants have to be in remission for at least 3 years (i.e. no psychiatric hospitalisation) under a stable antipsychotic medication. Remission will be measured using the remission criteria by Andreasen et al. (2005) Score ≤3 for the items concerning psychosis of the \""Positive and Negative Syndrom Scale\"" (PANSS; Kay et al., 1987): \""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) and a score ≤3 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976)\nAble to give informed consent\n\nExclusion Criteria:\n\nActively suicidal\nSerious medical illnesses\nKnown non-complience concerning the medication\nMedication with clozapin\nMedication with antidepressants and mood stabilisors that were initiated during the last 6 weeks before study enrollment\nPatients with substance dependence other than nicotine or caffeine within 6 months prior to baseline\nUnability to give informed consent\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse\n[ Time Frame: Every 2 weeks up to 26 weeks ]\n\n\n\nThe criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:\n\nScore ≥4 (moderate) for at least two of the following PANSS-items :\n\n\""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) (PANSS; Kay et al., 1987)\n\nScore ≥4 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976b)""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Psychiatric rehospitalisation\n[ Time Frame: Every 2 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Totalscore of Positive and Negative Syndrome Scale (PANSS)\n[ Time Frame: Baseline, then every 4 weeks up to 26 weeks ]\n\nPANSS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Occurence of specific adverse effects (open interview)\n[ Time Frame: Baseline,then every 4 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Clinical Global Impression - Severity Scale (CGI-S)\n[ Time Frame: Baseline, then every 4 weeks up to 26 weeks ]\n\nCGI-I Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""\""Quality of life\"" measured by the questionnaire \""Subjective well-being under neuroleptics scale\"" (SW-N)\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nSW-N-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Status of occupation\n[ Time Frame: Baseline, and after 12 and 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Personal and Social Performance (Personal and Social Performance Scale [PSP])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nPSP-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Adherence/Attitude of patients towards medication (Medication Adherence Rating Scale [MARS])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nMARS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Drop-outs total and due to specific reasons\n[ Time Frame: Every 2 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Movement disorders (Abnormal Involuntary Movement Scale [AIMS])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nAIMS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Weight change\n[ Time Frame: Baseline, and after 12 and 26 weeks ]""}]","[{""label"":""Study Officials:"",""content"":""Stefan Leucht, Professor\nPrincipal Investigator\nKlinikum rechts der Isar""},{""label"":""Study Officials:"",""content"":""Markus Dold, MD\nPrincipal Investigator\nKlinikum rechts der Isar""}]","[{""label"":""Sponsor:"",""content"":""Technische Universität München""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT02307396,3,3,2018-10-10,Completed,2015-02-01,2016-06-22,Actual,21,Actual,18,65,All,NA,No,"[""Inclusion Criteria:\n\nDiagnosis of schizophrenia or schizoaffective disorder\nThe participants have to be in remission for at least 3 years (i.e. no psychiatric hospitalisation) under a stable antipsychotic medication. Remission will be measured using the remission criteria by Andreasen et al. (2005) Score ≤3 for the items concerning psychosis of the \""Positive and Negative Syndrom Scale\"" (PANSS; Kay et al., 1987): \""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) and a score ≤3 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976)\nAble to give informed consent\n\nExclusion Criteria:\n\nActively suicidal\nSerious medical illnesses\nKnown non-complience concerning the medication\nMedication with clozapin\nMedication with antidepressants and mood stabilisors that were initiated during the last 6 weeks before study enrollment\nPatients with substance dependence other than nicotine or caffeine within 6 months prior to baseline\nUnability to give informed consent\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Relapse\n[ Time Frame: Every 2 weeks up to 26 weeks ]\n\n\n\nThe criterion is measured at every visit (every two weeks) two weeks with two criteria, both have to be fullfilled:\n\nScore ≥4 (moderate) for at least two of the following PANSS-items :\n\n\""Delusions\"" (P1), \""Conceptual disorganisation\"" (P2), \""Halluzinations\"" (P3), \""Mannerisms and posturing\"" (G5) and \""Unusual thought content\"" (G9) (PANSS; Kay et al., 1987)\n\nScore ≥4 on the \""Clinical Global Impression Severity Scale\"" (CGI-S; Guy, 1976b)""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Psychiatric rehospitalisation\n[ Time Frame: Every 2 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Totalscore of Positive and Negative Syndrome Scale (PANSS)\n[ Time Frame: Baseline, then every 4 weeks up to 26 weeks ]\n\nPANSS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Occurence of specific adverse effects (open interview)\n[ Time Frame: Baseline,then every 4 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Clinical Global Impression - Severity Scale (CGI-S)\n[ Time Frame: Baseline, then every 4 weeks up to 26 weeks ]\n\nCGI-I Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""\""Quality of life\"" measured by the questionnaire \""Subjective well-being under neuroleptics scale\"" (SW-N)\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nSW-N-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""Status of occupation\n[ Time Frame: Baseline, and after 12 and 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""Personal and Social Performance (Personal and Social Performance Scale [PSP])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nPSP-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""Adherence/Attitude of patients towards medication (Medication Adherence Rating Scale [MARS])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nMARS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""Drop-outs total and due to specific reasons\n[ Time Frame: Every 2 weeks up to 26 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""Movement disorders (Abnormal Involuntary Movement Scale [AIMS])\n[ Time Frame: Baseline, and after 12 and 26 weeks ]\n\nAIMS-Scale""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""Weight change\n[ Time Frame: Baseline, and after 12 and 26 weeks ]""}]","[{""label"":""Study Officials:"",""content"":""Stefan Leucht, Professor\nPrincipal Investigator\nKlinikum rechts der Isar""},{""label"":""Study Officials:"",""content"":""Markus Dold, MD\nPrincipal Investigator\nKlinikum rechts der Isar""}]","[{""label"":""Sponsor:"",""content"":""Technische Universität München""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00837603,1,3,2009-02-04,Not yet recruiting,2009-02-01,2010-08-01,Anticipated,48,Anticipated,18,40,All,NA,No,"[""Inclusion Criteria:\n\nage >=18 years\n\nExclusion Criteria:\n\ntricuspid regurgitation grade 2 or more\nsign. LVOTO or RVOTO\npacemaker or defibrillator\nrecent hospitalisation for heart failure (90 days)""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac MRI Right Ventricular Ejection Fraction\n[ Time Frame: 6 and 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary exercise capacity\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""laboratory markers of heart failure\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Diastolic RV and LV function\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Right ventricular volumes\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Right ventricular mass\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""NYHA-class\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""quality of life questionnaire\n[ Time Frame: 6 and 12 months ]""}]","[{""label"":""Central Contact Person:"",""content"":""Gerd P Meyer, MD\nTelephone: ++49-511-532 Ext. 3878\nEmail: meyer.gerdp@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Philip Roentgen, MD\nPrincipal Investigator\nHannover Medical School""},{""label"":""Study Officials:"",""content"":""Gerd P Meyer, MD\nStudy Chair\nHannover Medical School""},{""label"":""Study Officials:"",""content"":""Helmut Drexler, MD\nStudy Director\nHannover Medical School""}]","[{""label"":""Sponsor:"",""content"":""Hannover Medical School""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00837603,2,3,2009-02-12,Recruiting,2009-02-01,2010-08-01,Anticipated,48,Anticipated,18,40,All,NA,No,"[""Inclusion Criteria:\n\nage >=18 years\n\nExclusion Criteria:\n\ntricuspid regurgitation grade 2 or more\nsign. LVOTO or RVOTO\npacemaker or defibrillator\nrecent hospitalisation for heart failure (90 days)""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac MRI Right Ventricular Ejection Fraction\n[ Time Frame: 6 and 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary exercise capacity\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""laboratory markers of heart failure\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Diastolic RV and LV function\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Right ventricular volumes\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Right ventricular mass\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""NYHA-class\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""quality of life questionnaire\n[ Time Frame: 6 and 12 months ]""}]","[{""label"":""Central Contact Person:"",""content"":""Gerd P Meyer, MD\nTelephone: ++49-511-532 Ext. 3878\nEmail: meyer.gerdp@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Philip Roentgen, MD\nPrincipal Investigator\nHannover Medical School""},{""label"":""Study Officials:"",""content"":""Gerd P Meyer, MD\nStudy Chair\nHannover Medical School""},{""label"":""Study Officials:"",""content"":""Helmut Drexler, MD\nStudy Director\nHannover Medical School""}]","[{""label"":""Sponsor:"",""content"":""Hannover Medical School""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00837603,3,3,2012-03-08,Completed,2009-02-01,2010-09-01,Actual,48,Anticipated,18,40,All,NA,No,"[""Inclusion Criteria:\n\nage >=18 years\n\nExclusion Criteria:\n\ntricuspid regurgitation grade 2 or more\nsign. LVOTO or RVOTO\npacemaker or defibrillator\nrecent hospitalisation for heart failure (90 days)""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac MRI Right Ventricular Ejection Fraction\n[ Time Frame: 6 and 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary exercise capacity\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""laboratory markers of heart failure\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Diastolic RV and LV function\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Right ventricular volumes\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Right ventricular mass\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""NYHA-class\n[ Time Frame: 6 and 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""quality of life questionnaire\n[ Time Frame: 6 and 12 months ]""}]","[{""label"":""Study Officials:"",""content"":""Philip Roentgen, MD\nPrincipal Investigator\nHannover Medical School""},{""label"":""Study Officials:"",""content"":""Gerd P Meyer, MD\nStudy Chair\nHannover Medical School""},{""label"":""Study Officials:"",""content"":""Helmut Drexler, MD\nStudy Director\nHannover Medical School""}]","[{""label"":""Sponsor:"",""content"":""Hannover Medical School""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,1,14,2010-10-19,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Brage Garofalo\nTelephone: (650) 522-4732""},{""label"":""Study Officials:"",""content"":""David Oldach, MD\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,2,14,2010-11-01,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Brage Garofalo\nTelephone: (650) 522-4732""},{""label"":""Study Officials:"",""content"":""David Oldach, MD\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,3,14,2010-11-17,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Brage Garofalo\nTelephone: (650) 522-4732""},{""label"":""Study Officials:"",""content"":""David Oldach, MD\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,4,14,2010-12-09,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Brage Garofalo\nTelephone: (650) 522-4732""},{""label"":""Study Officials:"",""content"":""David Oldach, MD\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,5,14,2011-01-05,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Brage Garofalo\nTelephone: (650) 522-4732""},{""label"":""Study Officials:"",""content"":""David Oldach, MD\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,6,14,2011-02-24,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Brage Garofalo\nTelephone: (650) 522-4732""},{""label"":""Study Officials:"",""content"":""David Oldach, MD\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,7,14,2011-04-08,Recruiting,2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Central Contact Person:"",""content"":""Kristin Polsenski\nTelephone: (650) 522-6397""},{""label"":""Study Officials:"",""content"":""John McNally\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,8,14,2011-05-17,"Active, not recruiting",2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""John McNally\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,9,14,2011-08-18,"Active, not recruiting",2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""John McNally\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,10,14,2011-11-07,"Active, not recruiting",2010-10-01,2012-09-01,Anticipated,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""Phil Pang\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,11,14,2013-03-01,"Active, not recruiting",2010-10-01,2013-01-01,Actual,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""Bittoo Kanwar\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,12,14,2013-09-11,"Active, not recruiting",2010-10-01,2013-01-01,Actual,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""Bittoo Kanwar\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,13,14,2013-10-31,"Active, not recruiting",2010-10-01,2013-01-01,Actual,320,Anticipated,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""Bittoo Kanwar\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01225380,14,14,2013-12-20,Completed,2010-10-01,2013-01-01,Actual,324,Actual,18,70,All,NA,No,"[""Inclusion Criteria:\n\nAdult subjects 18 to 70 years of age\nChronic HCV infection for at least 6 months prior to Baseline (Day 1)\nLiver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis\nMonoinfection with HCV genotype 1a or 1b\nHCV treatment-naïve\nBody mass index (BMI) between 18 and 36 kg/m2\nCreatinine clearance >/= 50 mL/min\nSubject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nScreening laboratory values within defined thresholds for ALT, AST, leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH), potassium, magnesium\n\nExclusion Criteria:\n\nAutoimmune disease\nDecompensated liver disease or cirrhosis\nPoorly controlled diabetes mellitus\nSevere psychiatric illness\nSevere chronic obstructive pulmonary disease (COPD)\nSerological evidence of co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype\nSuspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers)\nHistory of hemoglobinopathy\nKnown retinal disease\nSubjects who are immunosuppressed\nSubjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse\nSubjects who are on or are expected to be on a potent cytochrome P450 (CYP) 3A4 or Pgp inhibitor, or a QT prolonging medication within 2 weeks of Baseline (Day 1) or during the study\nSubjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation\n[ Time Frame: 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events\n[ Time Frame: Through up to 48 weeks treatment period and 24 weeks of off-treatment follow-up ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256\n[ Time Frame: Through up to 48 weeks treatment period, 24 weeks of off-treatment follow-up, and up to 48 weeks of follow-up in the Resistance Registry Substudy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time\n[ Time Frame: Through Week 4 of therapy ]""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Long-term assessment of plasma HCV RNA in subjects who achieve SVR\n[ Time Frame: 36 months following Week 72 ]\n\nPlasma HCV RNA will be measured at approximately 6, 12, 24, and 36 months after Week 72.""}]","[{""label"":""Study Officials:"",""content"":""Bittoo Kanwar\nStudy Director\nGilead Sciences""}]","[{""label"":""Sponsor:"",""content"":""Gilead Sciences""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,1,52,2005-06-23,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,2,52,2005-08-02,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,3,52,2005-09-08,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,4,52,2005-11-03,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,5,52,2006-01-10,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,6,52,2006-02-09,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,7,52,2006-04-05,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,8,52,2006-05-02,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,9,52,2006-05-23,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,10,52,2006-06-07,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,11,52,2006-06-08,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,12,52,2006-08-24,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,13,52,2006-09-06,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,14,52,2006-09-29,Recruiting,NA,NA,NA,NA,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]",[],"[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,15,52,2006-11-08,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,16,52,2006-11-21,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,17,52,2007-01-11,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,18,52,2007-01-30,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,19,52,2007-04-09,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,20,52,2007-06-04,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,21,52,2007-06-06,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,22,52,2007-08-06,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,23,52,2007-09-18,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,24,52,2007-10-01,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,25,52,2007-10-13,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,26,52,2007-10-19,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,27,52,2007-10-25,Recruiting,NA,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,28,52,2007-11-02,Recruiting,2004-01-01,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,29,52,2007-11-09,Recruiting,2004-01-01,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,30,52,2007-11-14,Recruiting,2004-01-01,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,31,52,2007-12-11,Recruiting,2004-01-01,NA,NA,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,32,52,2007-12-25,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,33,52,2008-01-08,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,34,52,2008-02-06,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,35,52,2008-04-09,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,36,52,2008-04-25,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,37,52,2008-05-21,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,38,52,2008-05-22,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,39,52,2008-05-23,Recruiting,2004-01-01,2009-09-01,Anticipated,150,NA,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,40,52,2008-07-23,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,41,52,2008-12-02,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,42,52,2009-01-09,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,43,52,2009-02-06,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,44,52,2009-02-13,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,45,52,2009-02-24,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,46,52,2009-04-18,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,47,52,2009-06-09,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,48,52,2009-07-01,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,49,52,2009-10-06,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,50,52,2010-11-02,Recruiting,2004-01-01,2009-09-01,Anticipated,150,Anticipated,60,NA,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging at 5 years""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""University of Newcastle Upon-Tyne""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,51,52,2015-10-07,Completed,2004-01-01,2010-12-01,Actual,175,Actual,60,120,All,NA,No,"[""DISEASE CHARACTERISTICS:\n\nHistologically confirmed classical Hodgkin's lymphoma\nPreviously untreated disease\nNo nodular lymphocyte predominant Hodgkin's lymphoma\n\nPATIENT CHARACTERISTICS:\n\nAge\n\nOver 60\n\nPerformance status\n\nNot specified\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nNot specified\n\nHepatic\n\nNo significant hepatic abnormality that would preclude study participation\n\nRenal\n\nNo significant renal abnormality that would preclude study participation\n\nCardiovascular\n\nNo significant cardiac abnormality that would preclude study participation\n\nPulmonary\n\nNo significant pulmonary abnormality that would preclude study participation\n\nOther\n\n\""Non-fragile\"" status (i.e., mental and physical status must be sufficient to withstand study therapy)\nHIV negative\nNo other concurrent neoplasia\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNot specified\n\nChemotherapy\n\nNot specified\n\nEndocrine therapy\n\nNot specified\n\nRadiotherapy\n\nNot specified\n\nSurgery\n\nNot specified""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging\n[ Time Frame: 6 month intervals ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging\n[ Time Frame: 5 years ]""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD, FRCP, FRCPath\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nStudy Director\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nStudy Director\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""Newcastle-upon-Tyne Hospitals NHS Trust""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00079105,52,52,2017-03-29,Completed,2004-01-01,2010-12-01,Actual,175,Actual,60,120,All,NA,No,"[""Inclusion criteria:\n\nHistologically confirmed classical Hodgkin Lymphoma (HL). No previous treatment for HL. Age ≥ 60. \""Non fragile\"" patient (see Appendix 1) i.e. patient's mental and physical status must be sufficient to withstand the treatment described.\n\nNo concomitant neoplasia requiring treatment or known HIV infection. Written informed consent.\n\nExclusion criteria:\n\nNodular lymphocyte predominance Hodgkin Lymphoma (NLPHL) Age <60. Patient previously treated for HL. Known HIV infection or concomitant neoplasia. \""Fragile patient\"" (see Appendix 1) or significant abnormality of another system (pulmonary, cardiac, renal, and hepatic) which is a contraindication to full dose chemotherapy.\n\nUnable to give informed consent.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging\n[ Time Frame: 6 month intervals ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival by routine imaging\n[ Time Frame: 5 years ]""}]","[{""label"":""Study Officials:"",""content"":""Stephen J. Proctor, MD\nStudy Chair\nUniversity of Newcastle Upon-Tyne""},{""label"":""Study Officials:"",""content"":""Helen H. Lucraft, MD\nStudy Director\nNorthern Centre for Cancer Treatment at Newcastle General Hospital""},{""label"":""Study Officials:"",""content"":""Katrina M. Wood, MD\nStudy Director\nSir James Spence Institute of Child Health at Royal Victoria Infirmary""}]","[{""label"":""Sponsor:"",""content"":""Newcastle-upon-Tyne Hospitals NHS Trust""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,1,8,2013-05-15,Recruiting,2013-05-01,2015-05-01,Anticipated,400,Anticipated,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nCarotid artery stenosis of > 50% (NASCET) needing revascularisation and ipsilateral to ischemic territory.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism after 12 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death after 12 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,2,8,2013-05-16,Recruiting,2013-05-01,2015-05-01,Anticipated,400,Anticipated,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nCarotid artery stenosis of > 50% (NASCET) needing revascularisation and ipsilateral to ischemic territory.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,3,8,2013-10-28,Recruiting,2013-05-01,2015-05-01,Anticipated,400,Anticipated,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nSignificant carotid artery or vertebral artery stenosis > 50% (NASCET classification), significant intracranial artery stenosis suspicious of atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,4,8,2014-09-02,"Active, not recruiting",2013-05-01,2014-08-01,Actual,400,Anticipated,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nSignificant carotid artery or vertebral artery stenosis > 50% (NASCET classification), significant intracranial artery stenosis suspicious of atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,5,8,2014-09-18,"Active, not recruiting",2013-05-01,2015-02-01,Anticipated,400,Anticipated,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nSignificant carotid artery or vertebral artery stenosis > 50% (NASCET classification), significant intracranial artery stenosis suspicious of atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,6,8,2017-02-24,"Active, not recruiting",2013-05-01,2017-08-01,Anticipated,400,Anticipated,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nSignificant carotid artery or vertebral artery stenosis > 50% (NASCET classification), significant intracranial artery stenosis suspicious of atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,7,8,2020-01-09,Completed,2013-05-01,2017-09-01,Actual,402,Actual,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nSignificant carotid artery or vertebral artery stenosis > 50% (NASCET classification), significant intracranial artery stenosis suspicious of atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01855035,8,8,2020-04-30,Completed,2013-05-01,2017-09-01,Actual,402,Actual,60,NA,All,NA,No,"[""Inclusion Criteria:\n\nRecent cerebral ischemia defined as stroke (sudden focal neurologic deficit lasting > 24h consistent with the territory of a major cerebral artery and categorised as ischemic) and/or a corresponding lesion on brain imaging.\nStroke symptoms started ≤ 7 days ago.\nAge ≥ 60 years.\nModified Rankin scale ≤ 2 (prior to index event).\n\nExclusion Criteria:\n\nKnown history of atrial fibrillation/flutter or atrial fibrillation/flutter on admission ECG.\nIndication for oral anticoagulation at randomisation.\nAbsolute contra-indication against oral anticoagulation at randomisation.\nIntracerebral bleeding in medical history.\nPatient scheduled for Holter-ECG or cardiac Event-Recording monitoring ≥ 48 hours.\nSignificant carotid artery or vertebral artery stenosis > 50% (NASCET classification), significant intracranial artery stenosis suspicious of atherosclerotic origin or acute arterial dissection explanatory of stroke symptoms.\nImplanted pacemaker device or cardioverter/defibrillator.\nLife expectancy < 1 year for reasons other than stroke (e.g. metastatic cancer).\nConcomitant participation in other controlled randomised trial.""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation/flutter\n[ Time Frame: 30 month after study start ]\n\nThe primary endpoint is the detection of newly diagnosed atrial fibrillation/flutter within 6 months and before occurrence of recurrent stroke or systemic embolism in the treatment group compared to control group.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""number of atrial fibrillation (/flutter) within 12 months after patient's inclusion\n[ Time Frame: 24 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint but within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""number of atrial fibrillation (/flutter) without hospitalisation\n[ Time Frame: 30 months after study start ]\n\nDetection of newly diagnosed atrial fibrillation (/flutter) as defined for the primary endpoint with the exception that hospitalisation for atrial fibrillation (/flutter) will be considered as censoring.""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""number of recurrent stroke or systemic embolism\n[ Time Frame: 24 months after study start ]\n\nRecurrent stroke or systemic embolism within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""total mortality\n[ Time Frame: 24 months after study start ]\n\nTotal death within 12 months after patient's inclusion. As patients are recruited for 12 months, this outcome measure is determined 24 months after study start.""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""number of cardiovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""6."",""content"":""number of cerebrovascular deaths\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""7."",""content"":""number of transient ischemic attacks\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""8."",""content"":""number of myocardial infarctions\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""9."",""content"":""number of bleeding complications\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""10."",""content"":""quality of life\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""11."",""content"":""number of atrial fibrillation (/flutter) in extended monitoring period\n[ Time Frame: 24 months after study start ]\n\nIncremental detection of atrial fibrillation (/flutter) in the extended Holter monitoring periods after 3 and 6 months.""},{""section"":""Secondary Outcome Measures:"",""label"":""12."",""content"":""costs\n[ Time Frame: 24 months after study start ]""},{""section"":""Secondary Outcome Measures:"",""label"":""13."",""content"":""number of correct monitorings\n[ Time Frame: 24 months after study start ]\n\nTo assess the feasibility of monitoring procedures.""}]","[{""label"":""Study Officials:"",""content"":""Rolf Wachter, PD Dr. med.\nPrincipal Investigator\nDept. of Cardiology and Pneumology, University Medical Center Goettingen""},{""label"":""Study Officials:"",""content"":""Klaus Gröschel, PD Dr.med.\nPrincipal Investigator\nClinic and Policlinic for Neurology, University of Mainz""}]","[{""label"":""Sponsor:"",""content"":""Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01065337,1,3,2010-02-08,Completed,2005-08-01,2009-02-01,Actual,30,Actual,18,80,All,NA,No,"[""Inclusion Criteria:\n\nDiabetes mellitus Type 1 or 2\nPeripheral occlusive arterial disease stage III or IV (Fontaine) with chronical ischemia, chronic foot ulcer, degree of severity <5 (Wagner), older than 6 weeks, without acute wound infection\nUlcer size 1 - 30cm2, in case of osteomyelitis only one bone should be affected no trend towards healing in the ulcer after one week of standard treatment\nAngiopathic or angioneuropathic diabetic foot syndrome with no possible option of operative or interventional revascularisation\nAge 18 - 80 years\nDeclaration of patient consent""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred\n[ Time Frame: 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ABI values Improvement of tcpO2 Angiographical proven therapeutical effect Improvement of local perfusion\n[ Time Frame: 12 months ]""}]","[{""label"":""Study Officials:"",""content"":""Diethelm Tschoepe, Prof Dr Dr\nPrincipal Investigator\nHerz- und Diabeteszentrum NRW""}]","[{""label"":""Sponsor:"",""content"":""Ruhr University of Bochum""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01065337,2,3,2010-02-09,Completed,2005-08-01,2009-02-01,Actual,30,Actual,18,80,All,NA,No,"[""Inclusion Criteria:\n\nDiabetes mellitus Type 1 or 2\nPeripheral occlusive arterial disease stage III or IV (Fontaine) with chronical ischemia, chronic foot ulcer, degree of severity <5 (Wagner), older than 6 weeks, without acute wound infection\nUlcer size 1 - 30cm2, in case of osteomyelitis only one bone should be affected no trend towards healing in the ulcer after one week of standard treatment\nAngiopathic or angioneuropathic diabetic foot syndrome with no possible option of operative or interventional revascularisation\nAge 18 - 80 years\nDeclaration of patient consent""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred\n[ Time Frame: 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion\n[ Time Frame: 12 months ]""}]","[{""label"":""Study Officials:"",""content"":""Diethelm Tschoepe, Prof Dr Dr\nPrincipal Investigator\nHerz- und Diabeteszentrum NRW""}]","[{""label"":""Sponsor:"",""content"":""Ruhr University of Bochum""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01065337,3,3,2012-05-24,Completed,2005-08-01,2009-02-01,Actual,30,Actual,18,80,All,NA,No,"[""Inclusion Criteria:\n\nDiabetes mellitus Type 1 or 2\nPeripheral occlusive arterial disease stage III or IV (Fontaine) with chronical ischemia, chronic foot ulcer, degree of severity <5 (Wagner), older than 6 weeks, without acute wound infection\nUlcer size 1 - 30cm2, in case of osteomyelitis only one bone should be affected no trend towards healing in the ulcer after one week of standard treatment\nAngiopathic or angioneuropathic diabetic foot syndrome with no possible option of operative or interventional revascularisation\nAge 18 - 80 years\nDeclaration of patient consent""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred\n[ Time Frame: 12 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion\n[ Time Frame: 12 months ]""}]","[{""label"":""Study Officials:"",""content"":""Diethelm Tschoepe, Prof Dr Dr\nPrincipal Investigator\nHerz- und Diabeteszentrum NRW""}]","[{""label"":""Sponsor:"",""content"":""Ruhr University of Bochum""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Diethelm Tschoepe\n\nOfficial Title: Prof. Dr. Dr.\nAffiliation: Ruhr University of Bochum""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01049607,1,3,2010-01-13,Recruiting,2010-01-01,2011-10-01,Anticipated,190,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nPatients scheduled for elective hepatic resection\nStapler hepatectomy and clamp-crushing feasible based on preoperative imaging\nAge equal or greater than 18 years\nInformed consent\n\nExclusion Criteria:\n\nParticipation in concurrent intervention trials\nExpected lack of compliance\nImpaired mental state or language problems""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: 2.5 hours ]""}]","[{""label"":""Central Contact Person:"",""content"":""Nuh M Rahbari, MD\nTelephone: +49 6221 56 Ext. 39448\nEmail: nuh.rahbari@med.uni-heidelberg.de""},{""label"":""Central Contact Backup:"",""content"":""Jürgen Weitz, MD, MSc\nTelephone: +49 6221 56 Ext. 6250\nEmail: juergen.weitz@med.uni-heidelberg.de""},{""label"":""Study Officials:"",""content"":""Jürgen Weitz, MD, MSc\nPrincipal Investigator\nDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Heidelberg University""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01049607,2,3,2011-09-29,Recruiting,2010-01-01,2011-10-01,Anticipated,130,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nPatients scheduled for elective hepatic resection\nStapler hepatectomy and clamp-crushing feasible based on preoperative imaging\nAge equal or greater than 18 years\nInformed consent\n\nExclusion Criteria:\n\nParticipation in concurrent intervention trials\nExpected lack of compliance\nImpaired mental state or language problems""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: 2.5 hours ]""}]","[{""label"":""Central Contact Person:"",""content"":""Nuh N Rahbari, MD\nTelephone: +49 6221 56 Ext. 39448\nEmail: nuh.rahbari@med.uni-heidelberg.de""},{""label"":""Central Contact Backup:"",""content"":""Jürgen Weitz, MD, MSc\nTelephone: +49 6221 56 Ext. 6250\nEmail: juergen.weitz@med.uni-heidelberg.de""},{""label"":""Study Officials:"",""content"":""Jürgen Weitz, MD, MSc\nPrincipal Investigator\nDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Nuh Rahbari""},{""label"":""Responsible Party:"",""content"":""Sponsor-Investigator\nInvestigator: Nuh Rahbari\n\nOfficial Title: M.D. Resident\nAffiliation: Heidelberg University""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01049607,3,3,2013-05-16,Completed,2010-01-01,2011-10-01,Actual,130,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nPatients scheduled for elective hepatic resection\nStapler hepatectomy and clamp-crushing feasible based on preoperative imaging\nAge equal or greater than 18 years\nInformed consent\n\nExclusion Criteria:\n\nParticipation in concurrent intervention trials\nExpected lack of compliance\nImpaired mental state or language problems""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intraoperative blood loss\n[ Time Frame: 2.5 hours ]""}]","[{""label"":""Study Officials:"",""content"":""Jürgen Weitz, MD, MSc\nPrincipal Investigator\nDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Nuh Rahbari""},{""label"":""Responsible Party:"",""content"":""Sponsor-Investigator\nInvestigator: Nuh Rahbari\n\nOfficial Title: M.D. Resident\nAffiliation: Heidelberg University""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01236807,1,4,2010-11-08,Not yet recruiting,2010-12-01,2014-12-01,Anticipated,918,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris CCS class II and III and either\n≥2 cardiovascular risk factors\nor positive exercise treadmill test\nSigned written informed consent\nage: at least 18 years\n\nExclusion Criteria:\n\ncontraindication to MR\ncontraindication to adenosine infusion\nEF≤ 30%\ninability to lie supine for 60 minutes\nprevious Coronary Artery Bypass Grafts\nrevascularization within the previous 6 months\ncardiac arrhythmias (atrial fibrillation, >20 ectopic beats/min)\npoor renal function (eGFR <30ml/min)\nbody weight > 140kg or waist perimeter > 95cm\nknown allergy to contrast media""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Individual MACE\n[ Time Frame: 1 year ]\n\nindividual components as defined above""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Other adverse events\n[ Time Frame: 1 year ]\n\nneed for revascularization after initial treatment within 1 year""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Course of symptoms (angina, breathlessness)\n[ Time Frame: 1 year ]\n\nCCS class, NYHA class""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Cost comparison\n[ Time Frame: 1 year ]\n\nCosts related to MR- and FFR-guided selection for revascularisation""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""changes in LV volumes and function\n[ Time Frame: 1 year ]""}]","[{""label"":""Central Contact Person:"",""content"":""Eike Nagel, Professor\nTelephone: +44 20 7188 7242\nEmail: eike.nagel@kcl.ac.uk""}]","[{""label"":""Sponsor:"",""content"":""King's College London""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Guy's and St Thomas' NHS Foundation Trust\nNational Institute for Health Research, United Kingdom\nBayer""}]"
NCT01236807,2,4,2011-01-24,Recruiting,2010-12-01,2014-12-01,Anticipated,918,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris CCS class II and III and either\n≥2 cardiovascular risk factors\nor positive exercise treadmill test\nSigned written informed consent\nage: at least 18 years\n\nExclusion Criteria:\n\ncontraindication to MR\ncontraindication to adenosine infusion\nEF≤ 30%\ninability to lie supine for 60 minutes\nprevious Coronary Artery Bypass Grafts\nrevascularization within the previous 6 months\ncardiac arrhythmias (atrial fibrillation, >20 ectopic beats/min)\npoor renal function (eGFR <30ml/min)\nbody weight > 140kg or waist perimeter > 95cm\nknown allergy to contrast media""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Individual MACE\n[ Time Frame: 1 year ]\n\nindividual components as defined above""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Other adverse events\n[ Time Frame: 1 year ]\n\nneed for revascularization after initial treatment within 1 year""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Course of symptoms (angina, breathlessness)\n[ Time Frame: 1 year ]\n\nCCS class, NYHA class""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Cost comparison\n[ Time Frame: 1 year ]\n\nCosts related to MR- and FFR-guided selection for revascularisation""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""changes in LV volumes and function\n[ Time Frame: 1 year ]""}]","[{""label"":""Central Contact Person:"",""content"":""Eike Nagel, Professor\nTelephone: +44 20 7188 7242\nEmail: eike.nagel@kcl.ac.uk""}]","[{""label"":""Sponsor:"",""content"":""King's College London""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Guy's and St Thomas' NHS Foundation Trust\nNational Institute for Health Research, United Kingdom\nBayer""}]"
NCT01236807,3,4,2015-03-30,Recruiting,2010-12-01,2016-06-01,Anticipated,918,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris CCS class II and III and either\n≥2 cardiovascular risk factors\nor positive exercise treadmill test\nSigned written informed consent\nage: at least 18 years\n\nExclusion Criteria:\n\ncontraindication to MR\ncontraindication to adenosine infusion\nEF≤ 30%\ninability to lie supine for 60 minutes\nprevious Coronary Artery Bypass Grafts\nrevascularization within the previous 6 months\ncardiac arrhythmias (atrial fibrillation, >20 ectopic beats/min)\npoor renal function (eGFR <30ml/min)\nbody weight > 140kg or waist perimeter > 95cm\nknown allergy to contrast media""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Individual MACE\n[ Time Frame: 1 year ]\n\nindividual components as defined above""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Other adverse events\n[ Time Frame: 1 year ]\n\nneed for revascularization after initial treatment within 1 year""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Course of symptoms (angina, breathlessness)\n[ Time Frame: 1 year ]\n\nCCS class, NYHA class""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Cost comparison\n[ Time Frame: 1 year ]\n\nCosts related to MR- and FFR-guided selection for revascularisation""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""changes in LV volumes and function\n[ Time Frame: 1 year ]""}]","[{""label"":""Central Contact Person:"",""content"":""Eike Nagel, Professor\nTelephone: +49 151 41974195\nEmail: eike.nagel@cardiac-imaging.org""},{""label"":""Study Officials:"",""content"":""Eike Nagel, MD, PhD\nPrincipal Investigator\nGoethe University Frankfurt""}]","[{""label"":""Sponsor:"",""content"":""King's College London""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Eike Nagel\n\nOfficial Title: Global Chief Investigator\nAffiliation: King's College London""},{""label"":""Collaborators:"",""content"":""Guy's and St Thomas' NHS Foundation Trust\nBayer""}]"
NCT01236807,4,4,2016-12-26,Completed,2010-12-01,2016-08-01,Actual,915,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris CCS class II and III and either\n≥2 cardiovascular risk factors\nor positive exercise treadmill test\nSigned written informed consent\nage: at least 18 years\n\nExclusion Criteria:\n\ncontraindication to MR\ncontraindication to adenosine infusion\nEF≤ 30%\ninability to lie supine for 60 minutes\nprevious Coronary Artery Bypass Grafts\nrevascularization within the previous 6 months\ncardiac arrhythmias (atrial fibrillation, >20 ectopic beats/min)\npoor renal function (eGFR <30ml/min)\nbody weight > 140kg or waist perimeter > 95cm\nknown allergy to contrast media""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of major adverse cardiac events (MACE)\n[ Time Frame: 1year ]\n\nComposite of all cause death, myocardial infarction and repeat revascularisation.""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Individual MACE\n[ Time Frame: 1 year ]\n\nindividual components as defined above""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Other adverse events\n[ Time Frame: 1 year ]\n\nneed for revascularization after initial treatment within 1 year""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Course of symptoms (angina, breathlessness)\n[ Time Frame: 1 year ]\n\nCCS class, NYHA class""},{""section"":""Secondary Outcome Measures:"",""label"":""4."",""content"":""Cost comparison\n[ Time Frame: 1 year ]\n\nCosts related to MR- and FFR-guided selection for revascularisation""},{""section"":""Secondary Outcome Measures:"",""label"":""5."",""content"":""changes in LV volumes and function\n[ Time Frame: 1 year ]""}]","[{""label"":""Study Officials:"",""content"":""Eike Nagel, MD, PhD\nPrincipal Investigator\nGoethe University Frankfurt""}]","[{""label"":""Sponsor:"",""content"":""King's College London""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Eike Nagel\n\nOfficial Title: Global Chief Investigator\nAffiliation: King's College London""},{""label"":""Collaborators:"",""content"":""Guy's and St Thomas' NHS Foundation Trust\nBayer""}]"
NCT01486329,1,6,2011-12-05,Not yet recruiting,2011-12-01,2012-12-01,Anticipated,37,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nWritten informed consent, signed and dated\nLocally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations\nMale or post-menopausal female\nAge above or equal to 18 years\nChemotherapy naïve within 60 days before screening visit except gemcitabine treatment\nKarnovsky index >70\nLife expectancy >3 months\nAdequate renal, hepatic, and bone marrow function\nAbsolute neutrophil count >1500/µL\nHemoglobin >10 g/dL\nPlatelets >75000/µL\nProthrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)\nAspartate aminotransferase <4 times ULN\nAlanine aminotransferase <4 times ULN\nTotal bilirubin <3 times ULN\nCreatinine clearance estimated according to Cockcroft-Gault >30 mL/min\nProteinuria <1 g protein on 24 h urine collection\n\nExclusion Criteria:\n\nState after pancreas resection (complete or partial)\nResectable disease\nDrug trial participation within 60 days before screening visit\nOther previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years\nPrior vaccination with Ty21a\nCardiovascular disease defined as:\nUncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)\nArterial thromboembolic event within 6 months before randomization including:\nMyocardial infarction\nUnstable angina pectoris\nCerebrovascular accident\nTransient ischemic attack\nCongestive heart failure New York Heart Association grade III to IV\nSerious ventricular arrhythmia requiring medication\nClinically significant peripheral artery disease > grade 2b according to Fontaine\nHemoptysis within 6 months before randomization\nEsophageal varices\nUpper or lower gastrointestinal bleeding within 6 months before randomization\nSignificant traumatic injury within 4 weeks before randomization\nNon-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion\nGastrointestinal fistula\nThrombolysis therapy within 4 weeks before randomization\nBowel obstruction within the last 30 days before screening visit\nLiver cirrhosis ≥ grade B according to Child-Pugh Score-Classification\nPresence of any acute or chronic systemic infection\nRadiotherapy within 4 weeks before randomization\nMajor surgical procedures, or open biopsy within 4 weeks before randomization\nFine needle aspiration within 7 days before randomization\nChronic concurrent therapy within 2 weeks before and during the double-blind study period with:\nCorticosteroids (except steroids for adrenal failure) or immunosuppressive agents\nAntibiotics\nBevacizumab\nAny epidermal growth factor receptor inhibitor\nChemotherapy except gemcitabine before Day 10\nMulti-drug resistant gram-negative germ\nPregnancy\nLactation\nInability to comply with study and/or follow-up procedures\nHistory of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications\nWomen of childbearing potential\nAny history of drug hypersensitivity\nAny condition which results in an undue risk for the patient during the study participation according to the investigator""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Immune response\n[ Time Frame: Up to 24 months ]\n\nNumber of immune positive patients""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Tumor staging\n[ Time Frame: Up to 24 months ]\n\nTumor staging according to RECIST criteria""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Tumor perfusion\n[ Time Frame: Up to 24 months ]\n\nTumor perfusion determined by DCE-MRI""}]","[{""label"":""Central Contact Person:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nTelephone: +49 6221 566986\nEmail: ksc@med.uni-heidelberg.de""},{""label"":""Study Officials:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nPrincipal Investigator\nUniversity Clinics, Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Vaximm GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01486329,2,6,2011-12-07,Recruiting,2011-12-01,2012-12-01,Anticipated,37,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nWritten informed consent, signed and dated\nLocally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations\nMale or post-menopausal female\nAge above or equal to 18 years\nChemotherapy naïve within 60 days before screening visit except gemcitabine treatment\nKarnovsky index >70\nLife expectancy >3 months\nAdequate renal, hepatic, and bone marrow function\nAbsolute neutrophil count >1500/µL\nHemoglobin >10 g/dL\nPlatelets >75000/µL\nProthrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)\nAspartate aminotransferase <4 times ULN\nAlanine aminotransferase <4 times ULN\nTotal bilirubin <3 times ULN\nCreatinine clearance estimated according to Cockcroft-Gault >30 mL/min\nProteinuria <1 g protein on 24 h urine collection\n\nExclusion Criteria:\n\nState after pancreas resection (complete or partial)\nResectable disease\nDrug trial participation within 60 days before screening visit\nOther previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years\nPrior vaccination with Ty21a\nCardiovascular disease defined as:\nUncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)\nArterial thromboembolic event within 6 months before randomization including:\nMyocardial infarction\nUnstable angina pectoris\nCerebrovascular accident\nTransient ischemic attack\nCongestive heart failure New York Heart Association grade III to IV\nSerious ventricular arrhythmia requiring medication\nClinically significant peripheral artery disease > grade 2b according to Fontaine\nHemoptysis within 6 months before randomization\nEsophageal varices\nUpper or lower gastrointestinal bleeding within 6 months before randomization\nSignificant traumatic injury within 4 weeks before randomization\nNon-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion\nGastrointestinal fistula\nThrombolysis therapy within 4 weeks before randomization\nBowel obstruction within the last 30 days before screening visit\nLiver cirrhosis ≥ grade B according to Child-Pugh Score-Classification\nPresence of any acute or chronic systemic infection\nRadiotherapy within 4 weeks before randomization\nMajor surgical procedures, or open biopsy within 4 weeks before randomization\nFine needle aspiration within 7 days before randomization\nChronic concurrent therapy within 2 weeks before and during the double-blind study period with:\nCorticosteroids (except steroids for adrenal failure) or immunosuppressive agents\nAntibiotics\nBevacizumab\nAny epidermal growth factor receptor inhibitor\nChemotherapy except gemcitabine before Day 10\nMulti-drug resistant gram-negative germ\nPregnancy\nLactation\nInability to comply with study and/or follow-up procedures\nHistory of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications\nWomen of childbearing potential\nAny history of drug hypersensitivity\nAny condition which results in an undue risk for the patient during the study participation according to the investigator""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Immune response\n[ Time Frame: Up to 24 months ]\n\nNumber of immune positive patients""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Tumor staging\n[ Time Frame: Up to 24 months ]\n\nTumor staging according to RECIST criteria""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Tumor perfusion\n[ Time Frame: Up to 24 months ]\n\nTumor perfusion determined by DCE-MRI""}]","[{""label"":""Central Contact Person:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nTelephone: +49 6221 566986\nEmail: ksc@med.uni-heidelberg.de""},{""label"":""Study Officials:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nPrincipal Investigator\nUniversity Clinics, Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Vaximm GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01486329,3,6,2014-02-04,Recruiting,2011-12-01,2014-10-01,Anticipated,72,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nWritten informed consent, signed and dated\nLocally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations\nMale or post-menopausal female\nAge above or equal to 18 years\nChemotherapy naïve within 60 days before screening visit except gemcitabine treatment\nKarnovsky index >70\nLife expectancy >3 months\nAdequate renal, hepatic, and bone marrow function\nAbsolute neutrophil count >1500/µL\nHemoglobin >10 g/dL\nPlatelets >75000/µL\nProthrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)\nAspartate aminotransferase <4 times ULN\nAlanine aminotransferase <4 times ULN\nTotal bilirubin <3 times ULN\nCreatinine clearance estimated according to Cockcroft-Gault >30 mL/min\nProteinuria <1 g protein on 24 h urine collection\n\nExclusion Criteria:\n\nState after pancreas resection (complete or partial)\nResectable disease\nDrug trial participation within 60 days before screening visit\nOther previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years\nPrior vaccination with Ty21a\nCardiovascular disease defined as:\nUncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)\nArterial thromboembolic event within 6 months before randomization including:\nMyocardial infarction\nUnstable angina pectoris\nCerebrovascular accident\nTransient ischemic attack\nCongestive heart failure New York Heart Association grade III to IV\nSerious ventricular arrhythmia requiring medication\nClinically significant peripheral artery disease > grade 2b according to Fontaine\nHemoptysis within 6 months before randomization\nEsophageal varices\nUpper or lower gastrointestinal bleeding within 6 months before randomization\nSignificant traumatic injury within 4 weeks before randomization\nNon-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion\nGastrointestinal fistula\nThrombolysis therapy within 4 weeks before randomization\nBowel obstruction within the last 30 days before screening visit\nLiver cirrhosis ≥ grade B according to Child-Pugh Score-Classification\nPresence of any acute or chronic systemic infection\nRadiotherapy within 4 weeks before randomization\nMajor surgical procedures, or open biopsy within 4 weeks before randomization\nFine needle aspiration within 7 days before randomization\nChronic concurrent therapy within 2 weeks before and during the double-blind study period with:\nCorticosteroids (except steroids for adrenal failure) or immunosuppressive agents\nAntibiotics\nBevacizumab\nAny epidermal growth factor receptor inhibitor\nChemotherapy except gemcitabine before Day 10\nMulti-drug resistant gram-negative germ\nPregnancy\nLactation\nInability to comply with study and/or follow-up procedures\nHistory of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications\nWomen of childbearing potential\nAny history of drug hypersensitivity\nAny condition which results in an undue risk for the patient during the study participation according to the investigator""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Immune response\n[ Time Frame: Up to 24 months ]\n\nNumber of immune positive patients""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Tumor staging\n[ Time Frame: Up to 24 months ]\n\nTumor staging according to RECIST criteria""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Tumor perfusion\n[ Time Frame: Up to 24 months ]\n\nTumor perfusion determined by DCE-MRI""}]","[{""label"":""Central Contact Person:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nTelephone: +49 6221 566986\nEmail: ksc@med.uni-heidelberg.de""},{""label"":""Study Officials:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nPrincipal Investigator\nUniversity Clinics, Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Vaximm GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01486329,4,6,2014-06-26,"Active, not recruiting",2011-12-01,2014-10-01,Anticipated,72,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nWritten informed consent, signed and dated\nLocally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations\nMale or post-menopausal female\nAge above or equal to 18 years\nChemotherapy naïve within 60 days before screening visit except gemcitabine treatment\nKarnovsky index >70\nLife expectancy >3 months\nAdequate renal, hepatic, and bone marrow function\nAbsolute neutrophil count >1500/µL\nHemoglobin >10 g/dL\nPlatelets >75000/µL\nProthrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)\nAspartate aminotransferase <4 times ULN\nAlanine aminotransferase <4 times ULN\nTotal bilirubin <3 times ULN\nCreatinine clearance estimated according to Cockcroft-Gault >30 mL/min\nProteinuria <1 g protein on 24 h urine collection\n\nExclusion Criteria:\n\nState after pancreas resection (complete or partial)\nResectable disease\nDrug trial participation within 60 days before screening visit\nOther previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years\nPrior vaccination with Ty21a\nCardiovascular disease defined as:\nUncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)\nArterial thromboembolic event within 6 months before randomization including:\nMyocardial infarction\nUnstable angina pectoris\nCerebrovascular accident\nTransient ischemic attack\nCongestive heart failure New York Heart Association grade III to IV\nSerious ventricular arrhythmia requiring medication\nClinically significant peripheral artery disease > grade 2b according to Fontaine\nHemoptysis within 6 months before randomization\nEsophageal varices\nUpper or lower gastrointestinal bleeding within 6 months before randomization\nSignificant traumatic injury within 4 weeks before randomization\nNon-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion\nGastrointestinal fistula\nThrombolysis therapy within 4 weeks before randomization\nBowel obstruction within the last 30 days before screening visit\nLiver cirrhosis ≥ grade B according to Child-Pugh Score-Classification\nPresence of any acute or chronic systemic infection\nRadiotherapy within 4 weeks before randomization\nMajor surgical procedures, or open biopsy within 4 weeks before randomization\nFine needle aspiration within 7 days before randomization\nChronic concurrent therapy within 2 weeks before and during the double-blind study period with:\nCorticosteroids (except steroids for adrenal failure) or immunosuppressive agents\nAntibiotics\nBevacizumab\nAny epidermal growth factor receptor inhibitor\nChemotherapy except gemcitabine before Day 10\nMulti-drug resistant gram-negative germ\nPregnancy\nLactation\nInability to comply with study and/or follow-up procedures\nHistory of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications\nWomen of childbearing potential\nAny history of drug hypersensitivity\nAny condition which results in an undue risk for the patient during the study participation according to the investigator""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Immune response\n[ Time Frame: Up to 24 months ]\n\nNumber of immune positive patients""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Tumor staging\n[ Time Frame: Up to 24 months ]\n\nTumor staging according to RECIST criteria""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Tumor perfusion\n[ Time Frame: Up to 24 months ]\n\nTumor perfusion determined by DCE-MRI""}]","[{""label"":""Study Officials:"",""content"":""Friedrich H Schmitz-Winnenthal, MD\nPrincipal Investigator\nUniversity Clinics, Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Vaximm GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01486329,5,6,2014-07-07,"Active, not recruiting",2011-12-01,2014-10-01,Anticipated,72,Anticipated,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nWritten informed consent, signed and dated\nLocally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations\nMale or post-menopausal female\nAge above or equal to 18 years\nChemotherapy naïve within 60 days before screening visit except gemcitabine treatment\nKarnovsky index >70\nLife expectancy >3 months\nAdequate renal, hepatic, and bone marrow function\nAbsolute neutrophil count >1500/µL\nHemoglobin >10 g/dL\nPlatelets >75000/µL\nProthrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)\nAspartate aminotransferase <4 times ULN\nAlanine aminotransferase <4 times ULN\nTotal bilirubin <3 times ULN\nCreatinine clearance estimated according to Cockcroft-Gault >30 mL/min\nProteinuria <1 g protein on 24 h urine collection\n\nExclusion Criteria:\n\nState after pancreas resection (complete or partial)\nResectable disease\nDrug trial participation within 60 days before screening visit\nOther previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years\nPrior vaccination with Ty21a\nCardiovascular disease defined as:\nUncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)\nArterial thromboembolic event within 6 months before randomization including:\nMyocardial infarction\nUnstable angina pectoris\nCerebrovascular accident\nTransient ischemic attack\nCongestive heart failure New York Heart Association grade III to IV\nSerious ventricular arrhythmia requiring medication\nClinically significant peripheral artery disease > grade 2b according to Fontaine\nHemoptysis within 6 months before randomization\nEsophageal varices\nUpper or lower gastrointestinal bleeding within 6 months before randomization\nSignificant traumatic injury within 4 weeks before randomization\nNon-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion\nGastrointestinal fistula\nThrombolysis therapy within 4 weeks before randomization\nBowel obstruction within the last 30 days before screening visit\nLiver cirrhosis ≥ grade B according to Child-Pugh Score-Classification\nPresence of any acute or chronic systemic infection\nRadiotherapy within 4 weeks before randomization\nMajor surgical procedures, or open biopsy within 4 weeks before randomization\nFine needle aspiration within 7 days before randomization\nChronic concurrent therapy within 2 weeks before and during the double-blind study period with:\nCorticosteroids (except steroids for adrenal failure) or immunosuppressive agents\nAntibiotics\nBevacizumab\nAny epidermal growth factor receptor inhibitor\nChemotherapy except gemcitabine before Day 10\nMulti-drug resistant gram-negative germ\nPregnancy\nLactation\nInability to comply with study and/or follow-up procedures\nHistory of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications\nWomen of childbearing potential\nAny history of drug hypersensitivity\nAny condition which results in an undue risk for the patient during the study participation according to the investigator""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Immune response\n[ Time Frame: Up to 24 months ]\n\nNumber of immune positive patients""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Tumor staging\n[ Time Frame: Up to 24 months ]\n\nTumor staging according to RECIST criteria""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Tumor perfusion\n[ Time Frame: Up to 24 months ]\n\nTumor perfusion determined by DCE-MRI""}]","[{""label"":""Study Officials:"",""content"":""Thomas Schmidt, MD\nPrincipal Investigator\nUniversity Clinics, Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Vaximm GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01486329,6,6,2015-06-05,Completed,2011-12-01,2014-10-01,Actual,72,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nWritten informed consent, signed and dated\nLocally advanced, inoperable and stage IV pancreatic cancer patients according to UICC based on diagnostic imaging using computer-tomography (CT) or histological examinations\nMale or post-menopausal female\nAge above or equal to 18 years\nChemotherapy naïve within 60 days before screening visit except gemcitabine treatment\nKarnovsky index >70\nLife expectancy >3 months\nAdequate renal, hepatic, and bone marrow function\nAbsolute neutrophil count >1500/µL\nHemoglobin >10 g/dL\nPlatelets >75000/µL\nProthrombin time and international normalized ratio (INR) <1.5 times upper limit of normal (ULN) (except under anticoagulant treatment)\nAspartate aminotransferase <4 times ULN\nAlanine aminotransferase <4 times ULN\nTotal bilirubin <3 times ULN\nCreatinine clearance estimated according to Cockcroft-Gault >30 mL/min\nProteinuria <1 g protein on 24 h urine collection\n\nExclusion Criteria:\n\nState after pancreas resection (complete or partial)\nResectable disease\nDrug trial participation within 60 days before screening visit\nOther previous or current malignancy except basal or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for <2 years\nPrior vaccination with Ty21a\nCardiovascular disease defined as:\nUncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg)\nArterial thromboembolic event within 6 months before randomization including:\nMyocardial infarction\nUnstable angina pectoris\nCerebrovascular accident\nTransient ischemic attack\nCongestive heart failure New York Heart Association grade III to IV\nSerious ventricular arrhythmia requiring medication\nClinically significant peripheral artery disease > grade 2b according to Fontaine\nHemoptysis within 6 months before randomization\nEsophageal varices\nUpper or lower gastrointestinal bleeding within 6 months before randomization\nSignificant traumatic injury within 4 weeks before randomization\nNon-healing wound, bone fracture or any history of gastrointestinal ulcers within three years before inclusion, or positive gastroscopy within 3 months before inclusion\nGastrointestinal fistula\nThrombolysis therapy within 4 weeks before randomization\nBowel obstruction within the last 30 days before screening visit\nLiver cirrhosis ≥ grade B according to Child-Pugh Score-Classification\nPresence of any acute or chronic systemic infection\nRadiotherapy within 4 weeks before randomization\nMajor surgical procedures, or open biopsy within 4 weeks before randomization\nFine needle aspiration within 7 days before randomization\nChronic concurrent therapy within 2 weeks before and during the double-blind study period with:\nCorticosteroids (except steroids for adrenal failure) or immunosuppressive agents\nAntibiotics\nBevacizumab\nAny epidermal growth factor receptor inhibitor\nChemotherapy except gemcitabine before Day 10\nMulti-drug resistant gram-negative germ\nPregnancy\nLactation\nInability to comply with study and/or follow-up procedures\nHistory of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the study results or render the patient at high risk for treatment complications\nWomen of childbearing potential\nAny history of drug hypersensitivity\nAny condition which results in an undue risk for the patient during the study participation according to the investigator""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability\n[ Time Frame: 38 days ]\n\nNumber of dose-limiting toxicities and maximum tolerated dose""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Immune response\n[ Time Frame: Up to 24 months ]\n\nNumber of immune positive patients""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Tumor staging\n[ Time Frame: Up to 24 months ]\n\nTumor staging according to RECIST criteria""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Tumor perfusion\n[ Time Frame: Up to 24 months ]\n\nTumor perfusion determined by DCE-MRI""}]","[{""label"":""Study Officials:"",""content"":""Thomas Schmidt, MD\nPrincipal Investigator\nUniversity Clinics, Heidelberg""}]","[{""label"":""Sponsor:"",""content"":""Vaximm GmbH""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00893373,1,4,2009-05-04,Recruiting,2009-03-01,2011-05-01,Anticipated,276,Anticipated,18,60,All,NA,No,"[""Inclusion criteria\n\nPatients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)\nBone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of nonerythroid cells in the bone marrow must be leukemic blasts. In AML defined by cytogenetic aberrations, the proportion of blasts may be < 20%.\nAge ≥ 18 and ≤ 60 years\nInformed consent, personally signed and dated to participate in the study\nECOG performance status of 0-1\nLife expectancy of at least 12 weeks\nAdequate liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Rate of complete remissions\n[ Time Frame: 12 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Toxicity\n[ Time Frame: 36 months ]""}]","[{""label"":""Central Contact Person:"",""content"":""Christoph Rollig, MD\nTelephone: +49 351 458 - 0 Ext. 3775\nEmail: christoph.roellig@uniklinikum-dresden.de""},{""label"":""Central Contact Backup:"",""content"":""Malte von Bonin, MD\nTelephone: +49 351 458 - 0 Ext. 8110\nEmail: malte.bonin@uniklinikum-dresden.de""},{""label"":""Study Officials:"",""content"":""Gerhard Ehninger, Prof, MD\nPrincipal Investigator\nUniversity Hospital Dresden""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Carl Gustav Carus""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Bayer""}]"
NCT00893373,2,4,2009-05-28,Recruiting,2009-03-01,2011-05-01,Anticipated,276,Anticipated,18,60,All,NA,No,"[""Inclusion criteria\n\nPatients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)\nBone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of nonerythroid cells in the bone marrow must be leukemic blasts. In AML defined by cytogenetic aberrations, the proportion of blasts may be < 20%.\nAge ≥ 18 and ≤ 60 years\nInformed consent, personally signed and dated to participate in the study\nECOG performance status of 0-1\nLife expectancy of at least 12 weeks\nAdequate liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Rate of complete remissions\n[ Time Frame: 12 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Toxicity\n[ Time Frame: 36 months ]""}]","[{""label"":""Central Contact Person:"",""content"":""Christoph Rollig, MD\nTelephone: +49 351 458 - 0 Ext. 3775\nEmail: christoph.roellig@uniklinikum-dresden.de""},{""label"":""Central Contact Backup:"",""content"":""Malte von Bonin, MD\nTelephone: +49 351 458 - 0 Ext. 8110\nEmail: malte.bonin@uniklinikum-dresden.de""},{""label"":""Study Officials:"",""content"":""Gerhard Ehninger, Prof, MD\nPrincipal Investigator\nUniversity Hospital Dresden""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Carl Gustav Carus""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Bayer""}]"
NCT00893373,3,4,2012-02-02,Completed,2009-03-01,2011-11-01,Actual,276,Actual,18,60,All,NA,No,"[""Inclusion criteria\n\nPatients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)\nBone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of nonerythroid cells in the bone marrow must be leukemic blasts. In AML defined by cytogenetic aberrations, the proportion of blasts may be < 20%.\nAge ≥ 18 and ≤ 60 years\nInformed consent, personally signed and dated to participate in the study\nECOG performance status of 0-1\nLife expectancy of at least 12 weeks\nAdequate liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Rate of complete remissions\n[ Time Frame: 12 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Toxicity\n[ Time Frame: 36 months ]""}]","[{""label"":""Study Officials:"",""content"":""Gerhard Ehninger, Prof, MD\nPrincipal Investigator\nUniversity Hospital Dresden""}]","[{""label"":""Sponsor:"",""content"":""Technische Universität Dresden""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""Bayer""}]"
NCT00893373,4,4,2016-02-04,Completed,2009-03-01,2011-11-01,Actual,276,Actual,18,60,All,NA,No,"[""Inclusion criteria:\n\nPatients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML)\nBone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of nonerythroid cells in the bone marrow must be leukemic blasts. In AML defined by cytogenetic aberrations, the proportion of blasts may be < 20%.\nAge ≥ 18 and ≤ 60 years\nInformed consent, personally signed and dated to participate in the study\nECOG performance status of 0-1\nLife expectancy of at least 12 weeks\nAdequate liver and renal function as assessed by laboratory requirements to be conducted within 7 days prior to Screening\n\nExclusion criteria:\n\nPatients who are not eligible for standard chemotherapy as per discretion of the treating physician\nCentral nervous system manifestation of AML\nCardiac disease: heart failure NYHA III or IV; unstable coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)\nChronically impaired renal function (creatinine clearance < 30 ml/min) (Cockcroft-Gault formula)\nPatients undergoing renal dialysis\nChronic pulmonary disease with relevant hypoxia\nKnown HIV and/or hepatitis C infection\nEvidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy\nEvidence or recent history of CNS disease, including primary or metastatic brain tumors, seizure disorders\nResting blood pressure (BP) consistently higher than systolic 160 mmHg and/or diastolic 95 mmHg\nAny severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance of the protocol\nPatients with major surgery, open biopsy or significant traumatic injury within 4 weeks of start of first dose\nSerious, non-healing wound, ulcer or bone fracture\nUncontrolled active infection > Grade 2 NCI-CTC version 3.0\nConcurrent malignancies other than AML\nHistory of organ allograft\nAllergy to study medication or excipients in study medication""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: 36 months ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""Rate of complete remissions\n[ Time Frame: 12 weeks ]""},{""section"":""Secondary Outcome Measures:"",""label"":""3."",""content"":""Toxicity\n[ Time Frame: 36 months ]""}]","[{""label"":""Study Officials:"",""content"":""Gerhard Ehninger, Prof, MD\nPrincipal Investigator\nUniversity Hospital Dresden""}]","[{""label"":""Sponsor:"",""content"":""Technische Universität Dresden""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""Bayer""}]"
NCT00359918,1,5,2006-08-01,Recruiting,2006-08-01,NA,NA,160,NA,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris < 3 hours\nST-elevation myocardial infarction\n\nExclusion Criteria:\n\nActive bleeding\nActive gastric ulcus\nPrevious stroke\nUncontrolled hypertension (> 200 mmHg)\nCerebral surgery < 8 weeks\nMajor surgery < 4 weeks\nMalignancy\nTreatment with coumadine\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Clinical endpoints (bleeding, death, Re-MI, stroke)""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""ST-segment resolution""}]","[{""label"":""Central Contact Person:"",""content"":""Holger Thiele, MD, PhD\nTelephone: +493418651428\nEmail: thielh@medizin.uni-leipzig.de""},{""label"":""Study Officials:"",""content"":""Holger Thiele, MD, PhD\nPrincipal Investigator\nHeart Center Leipzig - University Hospital""}]","[{""label"":""Sponsor:"",""content"":""University of Leipzig""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00359918,2,5,2006-09-07,Recruiting,2006-08-01,NA,NA,160,NA,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris < 3 hours\nST-elevation myocardial infarction\n\nExclusion Criteria:\n\nActive bleeding\nActive gastric ulcus\nPrevious stroke\nUncontrolled hypertension (> 200 mmHg)\nCerebral surgery < 8 weeks\nMajor surgery < 4 weeks\nMalignancy\nTreatment with coumarines\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Clinical endpoints (bleeding, death, Re-MI, stroke)""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""ST-segment resolution""}]","[{""label"":""Central Contact Person:"",""content"":""Holger Thiele, MD, PhD\nTelephone: +493418651428\nEmail: thielh@medizin.uni-leipzig.de""},{""label"":""Study Officials:"",""content"":""Holger Thiele, MD, PhD\nPrincipal Investigator\nHeart Center Leipzig - University Hospital""}]","[{""label"":""Sponsor:"",""content"":""University of Leipzig""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00359918,3,5,2007-04-19,Recruiting,2006-08-01,NA,NA,160,NA,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris < 3 hours\nST-elevation myocardial infarction\n\nExclusion Criteria:\n\nActive bleeding\nActive gastric ulcus\nPrevious stroke\nUncontrolled hypertension (> 200 mmHg)\nCerebral surgery < 8 weeks\nMajor surgery < 4 weeks\nMalignancy\nTreatment with coumarines\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Clinical endpoints (bleeding, death, Re-MI, stroke)""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""ST-segment resolution""}]","[{""label"":""Central Contact Person:"",""content"":""Holger Thiele, MD, PhD\nTelephone: +493418651428\nEmail: thielh@medizin.uni-leipzig.de""},{""label"":""Study Officials:"",""content"":""Holger Thiele, MD, PhD\nPrincipal Investigator\nHeart Center Leipzig - University Hospital""}]","[{""label"":""Sponsor:"",""content"":""University of Leipzig""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00359918,4,5,2009-08-06,Completed,2006-08-01,2009-08-01,Actual,162,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris < 3 hours\nST-elevation myocardial infarction\n\nExclusion Criteria:\n\nActive bleeding\nActive gastric ulcus\nPrevious stroke\nUncontrolled hypertension (> 200 mmHg)\nCerebral surgery < 8 weeks\nMajor surgery < 4 weeks\nMalignancy\nTreatment with coumarines\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI\n[ Time Frame: 1-6 days ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Clinical endpoints (bleeding, death, Re-MI, stroke)""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""ST-segment resolution""}]","[{""label"":""Study Officials:"",""content"":""Holger Thiele, MD, PhD\nPrincipal Investigator\nHeart Center Leipzig - University Hospital""}]","[{""label"":""Sponsor:"",""content"":""University of Leipzig""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""""}]"
NCT00359918,5,5,2018-06-21,Completed,2006-08-01,2009-08-01,Actual,162,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nAngina pectoris < 3 hours\nST-elevation myocardial infarction\n\nExclusion Criteria:\n\nActive bleeding\nActive gastric ulcus\nPrevious stroke\nUncontrolled hypertension (> 200 mmHg)\nCerebral surgery < 8 weeks\nMajor surgery < 4 weeks\nMalignancy\nTreatment with coumarines\nPregnancy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI\n[ Time Frame: 1-6 days ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Clinical endpoints (bleeding, death, Re-MI, stroke)\n[ Time Frame: 30 days ]""},{""section"":""Secondary Outcome Measures:"",""label"":""2."",""content"":""ST-segment resolution\n[ Time Frame: 90 min ]""}]","[{""label"":""Study Officials:"",""content"":""Holger Thiele, MD, PhD\nPrincipal Investigator\nHeart Center Leipzig - University Hospital""}]","[{""label"":""Sponsor:"",""content"":""Holger Thiele""},{""label"":""Responsible Party:"",""content"":""Sponsor-Investigator\nInvestigator: Holger Thiele\n\nOfficial Title: PI\nAffiliation: University of Leipzig""},{""label"":""Collaborators:"",""content"":""""}]"
NCT03860129,1,1,2019-02-28,Completed,2014-12-10,2017-05-05,Actual,30,Actual,18,NA,All,NA,No,"[""Inclusion Criteria:\n\nSigning of the informed consent document (patient or relatives).\nPatient age 18 years or older.\nASA I-III\n\nExclusion Criteria:\n\nASA IV patients\nEpidural or spinal analgesia\nAllergy or known hypersensitivity to any of the study drugs\nPatients with known or suspected genetic susceptibility to malignant hyperthermia\nPrevious participation in this trial\nParticipation in another clinical trial within 4 weeks prior to selection.\nPregnant women""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""usage of volatile anesthetics at 0.5 MAC during ICU Sedation\n[ Time Frame: up to one week ]\n\nComparison between Isofluarne, Sevoflurane and Desflurane""}]","[{""label"":""Study Officials:"",""content"":""Thomas Weber, PhD\nPrincipal Investigator\nRuhr-University of Bochum, Germany""}]","[{""label"":""Sponsor:"",""content"":""Ruhr University of Bochum""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Martin Bellgardt\n\nOfficial Title: Prof. Dr. med. Thomas Weber, Director Anesthesiology department St. Josef-Hospitital\nAffiliation: Ruhr University of Bochum""},{""label"":""Collaborators:"",""content"":""""}]"
NCT01993056,1,1,2013-11-22,Completed,2011-08-01,2012-06-01,Actual,265,Actual,32,NA,Male,NA,Yes,"[""Inclusion Criteria:\n\nmale veteran soccer players aged 32 and older, who are member of a club veteran team; training and matches on a regular basis\n\nExclusion Criteria:\n\nmajor time-loss injury, chronic inflammatory joint disease""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""injury incidence\n[ Time Frame: August 2011 - June 2012 ]\n\ninjury incidence (injuries per 1000h of soccer)""}]","[{""label"":""Study Officials:"",""content"":""Daniel Hammes\nPrincipal Investigator\nSaarland University, Institute for Sports and Preventive Medicine""}]","[{""label"":""Sponsor:"",""content"":""Universität des Saarlandes""},{""label"":""Responsible Party:"",""content"":""Principal Investigator\nInvestigator: Anne Krieg M.D.\n\nOfficial Title: Dr\nAffiliation: Universität des Saarlandes""},{""label"":""Collaborators:"",""content"":""FIFA-Medical Assessment and Research Centre (F-MARC), Zurich, Switzerland""}]"
NCT00111345,1,9,2005-06-23,Recruiting,2004-03-01,NA,NA,550,NA,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)251-83-56486\nEmail: aml@uni-muenster.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, PD Dr. med.\nTelephone: +49 (0)251-83-56486\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, PD Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,2,9,2005-09-08,Recruiting,2004-03-01,NA,NA,550,NA,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, PD Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, PD Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,3,9,2006-04-11,Recruiting,2004-03-01,NA,NA,550,NA,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, PD Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, PD Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,4,9,2007-03-28,Recruiting,2004-03-01,NA,NA,550,NA,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, PD Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, PD Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,5,9,2009-03-10,Recruiting,2004-03-01,2009-12-01,Anticipated,550,Anticipated,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity\n[ Time Frame: 5 years ]""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,6,9,2009-08-07,Recruiting,2004-03-01,2009-12-01,Anticipated,550,Anticipated,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity\n[ Time Frame: 5 years ]""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,7,9,2010-06-10,Recruiting,2004-03-01,2010-12-01,Anticipated,550,Anticipated,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity\n[ Time Frame: 5 years ]""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nUniversity Children's Hospital Muenster""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,8,9,2012-03-06,Recruiting,2004-03-01,2011-12-01,Actual,550,Anticipated,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity\n[ Time Frame: 5 years ]""}]","[{""label"":""Central Contact Person:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: aml-bfm@mh-hannover.de""},{""label"":""Central Contact Backup:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nTelephone: +49 (0)511-532-9123\nEmail: reinhardt.dirk@mh-hannover.de""},{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hannover""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
NCT00111345,9,9,2012-05-21,Unknown status,2004-03-01,2012-03-01,Actual,550,Actual,NA,18,All,NA,No,"[""Inclusion Criteria:\n\nAge from >0 to <\/=18 years\nDe novo AML, including children with Down syndrome, primary myelosarcomas or acute mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)\nAdmission to one of the member hospitals in Germany participating in the study AML-BFM 2004\n\nExclusion Criteria:\n\nChildren with pre-existing syndromes (except Down syndrome)\nAML as secondary malignancy\nAccompanying diseases which do not allow therapy according to the protocol\nPre-treatment for more than 14 days with another intensive induction therapy""]","[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""},{""section"":""Secondary Outcome Measures:"",""label"":""1."",""content"":""Cardiotoxicity\n[ Time Frame: 5 years ]""}]","[{""label"":""Study Officials:"",""content"":""Ursula Creutzig, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hannover""},{""label"":""Study Officials:"",""content"":""Dirk Reinhardt, Prof. Dr. med.\nPrincipal Investigator\nMedical School Hanover""}]","[{""label"":""Sponsor:"",""content"":""University Hospital Muenster""},{""label"":""Responsible Party:"",""content"":""Sponsor""},{""label"":""Collaborators:"",""content"":""Deutsche Krebshilfe e.V., Bonn (Germany)""}]"
